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Abstract
Thromboxane A2 (TXA2) contributes to cardiovascular disease (CVD) by activating platelets and vascular
smooth muscle cell constriction and proliferation. Despite their preclinical efficacy, pharmacological
antagonists of the TXA2 receptor (the TP), a G protein-coupled receptor (GPCR), have not been clinically
successful, raising interest in novel approaches to modifying TP function. We sought to examine
molecular mechanisms underlying auto-upregulation of the TP in response to agonist activation. We first
determined a lack of agonist-induced TP mRNA modulation, focusing our attention on post-translational
TP regulation. GPCR dimerization contributes to post-translational regulation of receptor expression and
function, therefore we characterized how TP forms dimers with itself (homodimerization) or other related
receptors (heterodimerization) and defined the relative affinities. To determine how disruption of TP
dimerization impacts its regulation and function, we targeted a GxxxGxxxL helical interaction motif,
reportedly involved in transmembrane protein-protein interactions between other membrane proteins and
GPCRs, that is located in the human TP's (α isoform) 5th transmembrane domain. We determined that
disruption of this motif suppressed TP agonist-induced Gq signaling and TPα homodimerization, but not
its cell surface expression, ligand affinity or Gq association. Heterodimerization of TPα with the
functionally opposing receptor for prostacyclin (the IP) shifts TPα to signal via the IP-Gs cascade
contributing to prostacyclin's restraint of TXA2 function. Interestingly, and in contrast to the TPα
homodimer, disruption of the TPα-TM5 GxxxGxxxL motif did not modify either TPα-IP heterodimerization
or its Gs-cAMP signaling. Our study indicates that distinct regions of the TPα receptor direct its homoand hetero- dimerization and normal homodimerization appears necessary for efficient TPα-Gq
activation. Targeting the TPα-TM5 GxxxGxxxL domain may allow development of biased TPα- homodimer
antagonists that avoid suppression of TPα-IP heterodimer's predicted beneficial "IP-like" effects. Such
novel therapeutics may prove superior in CVD compared to non-selective suppression of all TP functions
with TXA2 biosynthesis inhibitors or traditional TP antagonists.
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ABSTRACT

CHARACTERIZATION AND TARGETING OF THROMBOXANE RECEPTOR DIMERIZATION: A
GATEWAY TO NOVEL THERAPEUTIC DEVELOPMENTS
Alexander J. Frey
Emer M. Smyth

Thromboxane A2 (TXA2) contributes to cardiovascular disease (CVD) by
activating platelets and vascular smooth muscle cell constriction and
proliferation. Despite their preclinical efficacy, pharmacological antagonists of the
TXA2 receptor (the TP), a G protein-coupled receptor (GPCR), have not been
clinically successful, raising interest in novel approaches to modifying TP
function. We sought to examine molecular mechanisms underlying autoupregulation of the TP in response to agonist activation. We first determined a
lack of agonist-induced TP mRNA modulation, focusing our attention on posttranslational TP regulation. GPCR dimerization contributes to post-translational
regulation of receptor expression and function, therefore we characterized how
TP forms dimers with itself (homodimerization) or other related receptors
(heterodimerization) and defined the relative affinities. To determine how
disruption of TP dimerization impacts its regulation and function, we targeted a
GxxxGxxxL helical interaction motif, reportedly involved in transmembrane
protein-protein interactions between other membrane proteins and GPCRs, that
is located in the human TP’s ( isoform) 5th transmembrane domain. We
v

determined that disruption of this motif suppressed TP agonist-induced Gq
signaling and TP homodimerization, but not its cell surface expression, ligand
affinity or Gq association. Heterodimerization of TP with the functionally
opposing receptor for prostacyclin (the IP) shifts TP to signal via the IP-Gs
cascade contributing to prostacyclin’s restraint of TXA2 function. Interestingly,
and in contrast to the TP homodimer, disruption of the TP-TM5 GxxxGxxxL
motif did not modify either TP-IP heterodimerization or its Gs-cAMP signaling.
Our study indicates that distinct regions of the TP receptor direct its homo- and
hetero- dimerization and normal homodimerization appears necessary for
efficient TP-Gq activation. Targeting the TP-TM5 GxxxGxxxL domain may
allow development of biased TP- homodimer antagonists that avoid
suppression of TP-IP heterodimer’s predicted beneficial “IP-like” effects. Such
novel therapeutics may prove superior in CVD compared to non-selective
suppression of all TP functions with TXA2 biosynthesis inhibitors or traditional TP
antagonists.
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Chapter 1: INTRODUCTION

Thromboxane A2 biosynthesis
Thromboxane (TxA2) is generated by thromboxane synthase (TS) metabolism of
prostaglandin H2, the immediate product of cyclooxygenase (COX) action on
arachidonic acid (1–3). It has a half-life of about 30s prior to non-enzymatic
degradation into the inactive thromboxane B2 metabolite (4). Platelet COX-1, the
only COX isoform expressed in mature platelets, is the dominant source of TxA2
synthesis under normal conditions (5). Other cells, including macrophages and
monocytes, contribute to TxA2 generation via both COX-1 and COX-2 with the
latter isozyme being particularly relevant during inflammation (2, 6). COX and TS
also act on 5,8,11,14,17-eicosapentaenoic acid (EPA) to form TxA3, a less potent
relative of TxA2 believed to play a role in the cardioprotective effects of n-3
polyunsaturated fatty acids consumption, most frequently found in fish oils.

Physiological and pathophysiological actions of thromboxane A2
Actions in the vasculature
TxA2 acts as a local autocrine or paracrine mediator to mediate a range of
physiological and pathophysiological responses that include platelet activation,
vasoconstriction, and smooth muscle cell proliferation (3, 7–11). TxA2 acts in a
paracrine manner activating adjacent platelets to generate more TxA2 and
amplify the action of other, more potent, platelet agonists (12, 13). These
1

processes are of particular relevance to cardiovascular disease (CVD) in which
TXA2 generation is markedly elevated and expression of its receptor, the TP, is
increased (14–16). In humans inhibition of platelet COX-1 with low-dose aspirin
is widely used for prevention of heart attack and stroke (17–20), while in mouse
models of atherogenesis and injury-induced vascular proliferation or remodeling,
disease severity was blunted by antagonism or deletion of the TP (8, 21, 22).
Interestingly, in hyperlipidemic mice TP antagonist was more effective in
reducing atherogenesis that COX inhibition (23). This may reflect antagonism of
COX-independent TP ligands, such as the isoprostanes, free-radical derived
metabolites of arachidonic acid that can activate the TP in vivo (24). These and
other studies have placed significant emphasis on the TP as a therapeutic target
in CVD(8, 12, 23). Despite their potential, however, pharmacological antagonists
of the TP have been clinically disappointing compared to low-dose aspirin, in
large part because none replicate aspirin’s irreversible inhibitory effect on
platelets (12, 25–27).
Actions in the nervous system
Within the central nervous system, TxA2 acts to promote proliferation and survival
of oligodendricytes (28) as well as increased secretion of interleukin 6 (29) and
peripheral adrenal catecholamine (30). It is also involved in astrogliosis in
astrocytes and astrocytoma cells (31) as well as the dipsogenic response to
angiotensin II (32). In the peripheral nervous system, TxA2 can elicit pulmonary
and cardiovascular reflexes via stimulation of peripheral sensory neurons (33–
2

35) and has been implicated in transduction of allergic itching responses in a
murine model (36).
Other actions
In the kidney, TxA2 acts on mesangial cells to cause cell contraction and
proliferation (37, 38), modulate cellular ion fluxes (39), and has been implicated
in the progression of nephritis and nephrotic disease (40, 41). Within the immune
system, TxA2 stimulates apoptosis and DNA fragmentation of CD4+/CD8+ cells
(42) and modulates acquired immunity through various effects upon native T
cells (43). Additionally, studies report a role for TxA2 in inflammation in the lung
(44), heart (45), and liver (46), and in the pathophysiological development of
asthma, rhinitis, and atopic dermatitis (47–49). During carcinogenesis, TxA2 may
contribute to angiotensin II-induced neovascularization (50) and to metastasis
(11).

The thromboxane receptor
Structure
The TP is a class A cell-surface G protein-coupled receptor (GPCR) exhibiting
the typical seven-transmembrane domain structure characteristic of this class of
receptors (Figure 1). In humans, but not in other species, there are two splice
variants, the TPα and TPβ, which differ structurally only in their C termini. As
ligand binding domains for the receptor are considered to be located on
extracellular loops or transmembrane sites near the extracellular domain, the two
3

Figure 1: Snake plot of the human TPα. GxxxG motifs in the N terminal, first intracellular
second extracellular domains are indicated in orange. The TM5 GxxxGxxxL motif under
investigation in the second section of this work our study is highlighted in red.
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isoforms are thought to have identical ligand binding sites, an assumption that is
supported experimentally (51).
Transcription of the  and ß TP variants is modulated by different upstream
promoters (52, 53) and the isoforms both maintain differences in some of their
post-translational modifications, interacting proteins, and agonist-induced
regulation (54–59). In transfected CHO cells, for example, stimulation of cells
expressing TPα led to an increase in cAMP levels, while similar activation of
TPβ-transfected cells cause a decrease in cAMP, suggesting a preference for
coupling with Gs and Gi, respectively; however, both receptor isoforms responded
similarly to agonist in terms of inositol phosphate generation (56). In another
study, activation of either TPα or TPβ led to ERK1/2 phosphorylation. For TPαexpressing cells, this action was inhibited by H89, an inhibitor of protein kinase A,
whereas for TPβ-expressing cells it was abrogated through overexpression of
p115-RGS, which has an inhibitory action towards G12/13 (55). These and other
examples suggest that the unique C-termini of each isoform may provide
differential preferences of G protein association.
Despite these differences, studies have not established significant physiological
or pathophysiological divergence between the two TP isoforms (12). As Smyth
notes, however, the fact that only humans express both TP isoforms should be a
principal consideration in the analysis of in vivo studies of the receptor in model
organisms that lack TPβ (12). There is evidence for an anti-angiogenic role for
TxA2 via TPβ in the vasculature (60–62); at the same time, other studies have
5

shown that TxA2 is a positive regulator of blood vessel growth, particularly in
tumors, in murine models using SQ 29,548 to inhibit TP activation (11, 63).

Signaling
The TP is expressed in a wide variety of tissues and cells including platelets,
smooth muscle cells, endothelial cells, lungs, kidneys, heart, thymus, and spleen
(64–66). A number of tissues appear to express both splice variants (67, 68)
although TPα is the only isoform expressed in platelets (69). This thesis work
focused on the TP α isoform. Thus, unless otherwise noted, references made in
this thesis to “TP” refer to TPα. Research from our group and others has defined
the TP’s functional and regulatory pathways (51, 54, 69–72) (Figure 2). Signaling
via the TP can be transduced through multiple G protein pathways, including G q,
G11, G12/13, G15, G16, Gi, Gs and Gh (51), though some of these associations have
only been reported in isolated studies.
The two signaling pathways that appear most relevant to the biological actions of
TP are Gq and G12/13 (73), which stimulate the phospholipase-C pathway of
inositol phosphate/intracellular calcium elevation and RhoA activation,
respectively (74). TP-mediated signaling via Gq causes activation of
phospholiase C (75) and, through phosphoinositide hydrolysis, generation of
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), thereby mobilizing
intracellular Ca2+ and activating protein kinase C (PKC)(76–78). Signal
transduction via G12/13 follows the activation of RhoGEF (79) and the associated
6

Figure 2: Summary of the reported major and minor signaling pathways of TP activation.
TP primarily acts through activation of Gαq/11 and Gα12/13, with additional signaling having been
reported through activation of Gαs, Gαi, and Gh. Downstream effectors vary based on tissue or
cells of interest. Additionally, dissociation of the Gβγ subunit can lead to concurrent activation of
other signaling pathways.
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Rho signaling cascade, modulating such responses as regulation of the actin
cytoskeleton, cytokinesis, cell motility, contraction, cell proliferation, apoptosis,
thymic cellularity, Na+/H+ exchanger and myosin light chain kinase (51).
These systems both appear to contribute to platelet function - G12/13-mediated
stimulation of RhoA signaling induces myosin light chain phosphorylation leading
to platelet shape change, with subsequent activation of G q-PLCβ signaling
causing aggregation (80). In mice, platelets lacking Gq or G13 are completely
unresponsive to TxA2, showing that Gq and G13 are required for platelet activation
(74). It is also interesting to note that low concentrations of the TP agonist
U46619 are sufficient to cause platelet shape change, while high concentrations
are necessary to induce aggregation (81).
In addition to signaling through Gα subunits, studies have reported Gβγmediated activation of phosphatidylinositol 3-kinase (PI3K), phospholipase C-β2
and p44/42 mitogen-activated protein kinase (p44/42 MAPK)/extracellular signalregulated kinase 1/2 (ERK1/2), though the precise role in TP function and biology
has not been clearly defined (73, 82).

Regulation: Desensitization
The TP undergoes both homologous (following its own activation) and
heterologous (following activation of another receptor) desensitization (58, 83–
86) via phosphorylation of residues in the C-terminus. Here distinctions between
the unique C-termini of the two TP isoforms have been reported. For the TP
8

isoform, Ser329 is a phosphorylation site for protein kinase A (PKA) activated by
cAMP, allowing heterologous desensitization by Gs-coupled receptors like the
prostacyclin receptor (86). Ser331 is a target for protein kinase G (PKG)/cGMPmediated desensitization, and Thr337 is a site for protein kinase C (PKC)
phosphorylation (51).
The TPß, on the other hand, undergoes phosphorylation at Thr299 and Ser145 by
PKC (87), and at Ser357 (in tandem with Ser239) by G protein-coupled receptor
kinase (predominantly GRK2; lesser effects seen with GRK3, GRK5, or GRK6)
(88). GRK-mediated phosphorylation leads to recruitment of β-arrestin and
subsequent decoupling of G proteins from the receptor followed by internalization
(89). Arrestin-mediated internalization has been implicated in regulation of the
TPß contributing to lower basal surface expression levels of the receptor (54),
and its more ready internalization, compared to TP, following activation (88).
Of noteworthy relevance to the discussion of TP is an autoupregulation system
downstream of TP activation. Work by Wilson et al. uncovered a reactive oxygen
species (ROS)-dependent mechanism through which stimulation of the TP leads
to activation of NADPH oxidase, in turn leading to increased TP protein stability
in early biogenesis and, ultimately, increased receptor expression at the cell
surface (70). Though the mechanism underlying this pathway is as yet ill-defined,
exogenous ROS can also increase in TP protein stability and expression, which
may be particularly relevant in cardiovascular disease where ROS levels are
elevated (12).
9

Regulation: Intracellular trafficking
As previously noted, TPα has been seen to be generally expressed at higher
levels at the cell surface compared to TPβ, at least in the transfected cell models
found in the literature, likely because the latter binds to protosomal subunit α7
and proteasome activator PA28γ through the unique TPβ the C-terminal domain,
leading to TPβ degradation by PA28γ-dependent protease activity (90). TPβ
endocytosis also occurs in a Rac-1-dependent manner through interaction with
Nm23-H2 (91), a process that requires interaction with the actin cytoskeleton
(92). TPβ that has been thus internalized may be recycled to the cell surface
through an interaction with Rab11 and the its GTPase-positive recycling
endosome (57, 93). Studies disagree on whether or not TPα is internalized
suggesting that internalization of TPα may cell- or context- specific (88, 94).
Successful trafficking to the TP to the cell surface appears to be strictly
dependent on glycosylation of Asn4 and Asn16 at the N-terminus, a process
common to both isoforms. Treatment of TPα and TPβ with tunicamycin (a
specific inhibitor of N-linked glycosylation) significantly reduced the binding of SQ
29,548, a TP antagonist, in both isolated cell membranes (95) and whole stably
receptor-expressing cells (96). Further, targeted mutation of either of these sites
resulted in a reduction by half of the Bmax for SQ 29,548 binding, while mutation
of both lead to near-complete retention of the receptor within the endoplasmic
reticulum and failure to couple with G proteins (71).

10

Interplay between thromboxane and prostacyclin and their receptors
The actions of TxA2 are generally opposed by prostacyclin (PGI2), another shortlived prostanoid that is generated from arachidonic acid predominantly through
COX-2 and prostacyclin synthase in the vascular endothelium (97). Acting
though the prostacyclin receptor (IP), PGI2 inhibits platelet activation, reduces
vascular proliferation, and causes vasodilation (98). The IP is coupled to Gs,
thus activation leads to increased intracellular cyclic AMP generation. Mice
lacking the IP display heightened thrombotic responses (99) and accelerated
development of atherosclerosis (8). A critical function of the IP is to restrain TP
function – mice that lack the IP show increased platelet and proliferative
responses to vascular injury in vivo with the opposite phenotype in TP deficient
mice and normalization of both phenotypes in double receptor knock out animals
(21). With their opposing roles, the interplay between TxA2 and PGI2 is an
important component of cardiovascular function and disease and is particularly
relevant in later parts of this work.

G protein-Coupled Receptor Dimerization
Substantial evidence has emerged in the field of GPCR research that these
seven-transmembrane proteins do not function only as monomeric receptors in
physiological systems, but rather as dimeric, and possibly oligomeric, units (100–
103). Receptor dimerization appears necessary for normal physiological
signaling of some receptors (104, 105) and dimeric forms of GCPRs have
11

become a novel target for therapeutic research, with the goal of modifying
dimerization through the use of small molecules. Both homodimer and
heterodimer formation has been noted for a variety of GPCRs. For the GABAB
receptor, dimerization has been described as “obligatory”, with the pairing
necessary for proper biogenesis and receptor function (106, 107). In comparison,
dimer formation does not appear essential for other receptors, like the dopamine
receptor, but does modulate the receptor’s signaling response to agonist (108,
109). In addition, “‘non-obligatory’ GPCR heterodimer” formation has been noted
for a number of GPCRs (100), including the TP (see below) with significant
changes in downstream signaling of a given receptor when it forms a
heterodimer as compared to its homodimer (110, 111).
Dimerization may contribute early in GPRC biosynthesis (112) at certain qualitycontrol checkpoints (100). Homodimerization can occur early in the biosyntetic
pathway, most likely in the endoplasmic reticulum (112, 113), and is a
prerequisite for receptor trafficking to the cell surface for a number of other
GPCRs including the GABAB receptor (107), α1D- and α1B-adrenoceptors (114),
and β2-adrenergic receptor (115). Mutations that cause GCPR retention in the
ER/Golgi can act in a dominant-negative manner to block cell surface expression
of wild-type receptor (116, 117), as the mutants remain able to dimerize, yet
cannot pass through quality control checkpoints to exit the ER and continue
through biogenesis to be transported to the cell surface. These studies further
support the model that dimerization occurs early in the posttranslational biogenic
12

pathway, and have raised interest in developing ways to disrupt dimer formation
as a novel approach to modifying receptor function. For example, a small
molecule that prevents dimerization would also prevent cell surface expression,
an alternative approach to antagonism to reduce receptor function. If the target
receptor were one involved in disease pathophysiology, such as the TP in CVD,
then disease could be prevented or ameliorated.
Across the GPCR superfamily, there is substantial evidence for receptor
dimerization (118, 119) and a significant contribution therein to receptor
trafficking, ligand recognition, signaling and regulation (100, 102, 115, 120). As
mentioned above, previous work in our lab reported that the TP forms dimeric
receptor complexes (94, 121–123). In addition to homodimerization, TPα can
heterodimerize with TPβ, leading to enhanced isoprostane responsiveness (122).
Further, as part of the work outlined in this thesis, we observed equal propensity
for TPα to heterodimerize with the receptor for PGI2, the IP (123). As mentioned
above, the PGI2, a predominantly COX-2-derived mediator, acts via the IP to
activate the Gs-adenylyl cyclase signaling pathway causing vasodilation and
inhibition of platelet activation (98). In mice, the restraint placed by the PGI2-IP
system on TxA2-TP function limits the proliferative and platelet response to
vascular injury (21) demonstrating the in vivo relevance of this interplay. Further,
the elevated cardiovascular hazard in patients treated with COX-2 inhibitors can
be explained by selective suppression of COX-2-derived PGI2 without alteration
of COX-1-derived TXA2 levels (124). We determined that heterodimerization of
13

the TP with the IP contributes to the PGI2-TXA2 interplay - dimerization with the
IP dramatically shifts TP function from a lipid raft-excluded Gq-coupled receptor
to a raft-associated Gs-coupled receptor that yields a robust Gs-cAMP response,
concomitant with reduced Gq-inositol phosphate signaling, to TP agonists (121,
123). In effect therefore, the IP can bias the response of TXA2-TP toward a PGI2IP “like” signal predicted as beneficial in CVD. Loss of this shift in TP function in
individuals heterozygous for a signaling deficient IP mutant, IP R212C, may
contribute to their accelerated CVD (125).

Dimerization motifs as mediators of GPCR pairing
The importance of transmembrane (TM) helical interactions to protein structure
and function is evident across multiple diverse integral membrane protein
families (126, 127). Consequently, there is significant interest targeting TM
domains to modulate the function of membrane-spanning proteins, including
GPCRs (107, 118, 120, 128–130). Various studies, include those resolving
GPCR crystal structures (131), have shown that dimerization interfaces are
predominantly found in the TM domains (132–134).
Among all TM domains, a GxxxG motif, in which two glycines are separated by
any three other residues, is strongly over-represented (135), highly conserved
across species (136, 137) and can direct homologous or heterologous helical
interactions (126, 127, 138). Neighboring residues, especially the large aliphatic
residues isoleucine, valine and leucine, appear critical to GxxxG-mediated helix14

helix interactions (136, 137). In a number of proteins (139–142), including at least
two GPCRs (104, 115), placement of a leucine three residues after the second
glycine, to create a GxxxGxxxL motif, directs protein-protein interaction and
function. We identified a GxxxGxxxL motif within the 5th transmembrane of the
TPα (Figure 3) and, as part of this thesis research, examined its relevance for TP
function.

Current Therapeutics Targeting TXS and TP
Therapeutics that interfere with TP signaling generally act in one of three ways:
inhibition of COX-1/2 conversion of arachidonic acid to PGH2, inhibition of TXS
conversion of PGH2 to TxA2, or antagonism of the TP itself. Low-dose aspirin
which inhibits platelet COX-1-derived TxA2 is used widely to protection against
heart attack and stroke. Although true aspirin resistance is likely extremely rare
(143), heterogeneity in the beneficial response and weak benefit in some
pathophysiologies (e.g., diabetes, peripheral artery disease (144, 145), as well as
possible gender differences (146)) underscore the need for greater mechanistic
understanding to advance new therapeutic TXA2-TP approaches in CVD.
Over the past decade, attempts to use therapeutics that targeted TxA2 synthase
or the TP itself have generally met with limited to no clinical success. Most
recently, the selective TP receptor antagonist terutroban showed comparable,
but not superior, efficacy as low-dose aspirin in preventing recurrent ischemic
stroke in clinical trials (147). Other thromboxane receptor agonists include
15

G205
G209
L213

G205
G209
L213

Figure 3: Location and positioning of the GxxxGxxxL motif within the TP.
Homology modeling (SWISS-MODEL) of the human TPα based on a 2.8Å
crystallographic bovine rhodopsin template. Relative positions of G 205, G209 and L213 are
highlighted. Each appeared to face the lipid bi-layer aligned on one side of TM5.
(Credit: Scott Gleim/Hwa Lab, Yale University School of Medicine)
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ifetroban (148), seratrodast (used for treatment of asthma) (149), and sulotroban
(150).
A number of other drugs act as tandem TP antagonists/TxA2 synthesis inhibitors.
Dipyridamole has been shown to be effective in adjunctive therapy with aspirin
for secondary prevention following stroke (151). Picotamide is a platelet
aggregation inhibitor that has shown antiplatelet efficacy in some studies (152).
Ridogrel has been tested for use in helping to treat Crohn’s disease and
ulcerative colitis, but without promising results (153, 154).
Furegrelate is a potent inhibitor of thromboxane synthase with little effect on
other enzymes essential for arachidonate metabolism, and has been investigated
for use in treatment of pulmonary arterial hypertension with promising early
results in model animals (155). Ozagrel also acts to inhibit synthesis, and has
been seen to reduce neurological impairment suffered with stroke, though
without improving long-term morbidity or other endpoints (156).

Project aims
While previous work by Wilson established the presence of the ROS-dependent
auto-upregulation paradigm, the underlying mechanisms of TP regulation within
the cell remained ill-defined. As such, one aim of my thesis work sought to
explore the mechanism(s) for the increase in cell surface TP expression in
response to activation. One possibility was that stimulation of the receptor was
leading to an increase in mRNA levels, thus increasing TP protein levels.
17

However, quantitative real-time PCR analysis did not strongly support this
hypothesis.
In light of emerging evidence for dimerization as a mode of GPCR regulation, I
also sought to confirm TP homodimerization, which was apparent in coimmunoprecipitation studies previously performed in the laboratory. Not only was
I able to confirm TP homodimerization, I also characterized the relative efficiency
of TP interaction with other prostanoid receptors, including the IP and the DP1
receptor for prostaglandin D2.
The findings from dimerization studies in this first aim, taken together with
research in the literature describing the significance of the GxxxGxxxL helical
interaction motif, a motif we identified within the TPs 5th TM, led to the
development of the second aim. The second aim sought to determine if the
GxxxGxxxL motif contributed to TP dimerization and, if so, whether or not
targeting of this motif would be a novel therapeutic approach to suppress TP
function. We determined that the TP TM5 GxxxGxxxL motif does contribute to TP
dimer formation. Further, using mutant forms of the TP, we demonstrated that
this motif was selectively involved in TP homodimer formation and signaling but
not TP-IP heterodimerization or signaling by the TP-IP heterodimer. These
studies provided the first proof-of-principle that the homo- and hetero-dimeric
functions of the TP and TP-IP can be discriminated to suppress the CVDdeleterious TP function and preserve the CVD-beneficial TP-IP function.
Targeting of the TP GxxxGxxxL motif with a peptide, which was designed against
18

a similar transmembrane domain in the II integrin (128), provided an exciting
initial indication of the potential for targeting this region to develop a biased
therapeutic directed against the deleterious side of TP signaling. Full analysis of
these results and their implications follow.
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CHAPTER 2: Materials and Methods

Constructs
Hemagglutinin- (HA) tagged human IP and TPα cloned into the mammalian
expression vector pcDNA3 (Invitrogen, CA) were previously created in the lab
(123). QuikChange site-directed mutagenesis (Stragagene, CA) was used to
replace G205 and G209 with leucines, a small-to-large replacement that disrupts
helix-helix interaction (139, 141, 142). We replaced L213 with a tyrosine based on
the studies of the GxxxGxxxL motif in the ß2-adrenergic receptor(115). The
resulting mutant was termed TPL205,L209,Y213. Similar mutations were made at the
partial GxxxG motif at the beginning of the first intracellular loop to create the
TPL51,L55 mutant. See Table 1 for the list of primers designed for mutagenesis.
HA-tagged IP, TPα, and TPL205,L209,Y213 were fused at their C-termini to either
Renilla luciferase (rLuc) or yellow fluorescent protein (YFP), via restriction
enzyme cutting and reassembly after purification of DNA segments (157). Briefly,
the stop codon was removed by PCR and each stop-less construct cloned into
pRLuc-N3(h) (Perkin-Elmer, MA) and pEYFP-N1 (Clontech, CA) plasmids in
frame with the fusion protein start site. All sequences were verified by DNA
sequencing.
The TP first transmembrane domain (TM1) interacting peptide was created
through PCR amplification of the TP sequences between residues R23 and T59,
containing the entirety of TM1. This amplification product was inserted via
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Table 1: Sequences of primers used in the generation of mutants employed in this work.
Note that some primers must be used following the introduction of a prior mutation due to overlap
in the sequences.

Target
Mutation

Primer Sequence

G205xxxG209xxxL213 → G205xxxG209xxxY213
Sense

5'- CTG TCC TTC TAC CTG AAC ACG GTC -3'

Antisense

5'- GAC AGG AAG ATG GAC TTG TGC CAG -3'

G205xxxG209xxxY213 → G205xxxL209xxxY213
Sense
Antisense

5'- CC ATG CTG GGC GGC CTC TCG GTC TTG CTG TCC TTC -3'
5'- GAA GGA CAG CAA GAC CGA GAG GCC GCC CAG CAT GG -3'

G205xxxL209xxxY213 → L205xxxL209xxxY213
Sense
Antisense

5'- GG CTG CTC TTC TCC ATG CTG GGC CTC CTC TCG GTC -3'
5'- GAC CGA GAG GAG GCC CAG CAT GGA GAA GAG CAG CC -3'

G51xxxG55 → G51xxxL55
Sense

5'- CGC GCG GCA GTT GGG TTC GCA CAC GCG CTC -3'

Antisense

5'- GAG CGC GTG TGC GAA CCC AAC TGC CGC GCG -3'

G51xxxL55 → L51xxxL55
Sense

5'- CTG AGC GTG CTG GCG CTC GCG CGG CAT TG -3'

Antisense

5'- CAA TGC CGC GCG AGC GCC AGC ACG CTC AG -3'
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restriction enzyme digestion and religation, into the pNTAP vector obtained as
part of the InterPlay N-terminal Mammalian TAP System (Stratagene, LaJolla,
CA) to provide necessary the constitutive cytomegalovirus promoter and
SV40/poly-adenosine tail for stability (Figure 4).

Cell culture
HEK 293 and Meg-01 cell lines were from the American Type Tissue Culture
Collection (ATTC; Rockville, MD). HEK 293 cells were maintained following
established and published protocol in the lab (48); HEK cells were grown in
DMEM High Glucose medium (Invitrogen) containing 10% fetal bovine serum,
1% penicillin-strepomycin, 2mM L-glutamine, and 25mM HEPES buffer. Cells
were grown in 75 cm2 surface area flasks and passaged in a 1:4 ratio upon
reaching 80-90% confluency by allowing cells to lift in 37°C Hank’s Balanced Salt
Solution containing 0.02% EDTA prior to collection and redistribution into new
plates.
Meg-01 cells were grown in RPMI-1640 (Invitrogen) containing 10% fetal bovine
serum and 1% penicillin-strepomycin. Cells were grown in 20 mL of medium in
75 cm2 surface area flasks. Passaging was performed according to ATTC
literature that accompanied the cells, every 2-3 days by scraping the bottom of
the flask with a disposable cell scraper and addition of 5 mL of this cell
suspension to 15 mL of fresh medium in each new flask.
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Figure 4: Design of the TP TM1 interacting peptide. Sequence excerpted from the TP
sequence for creation of the TP TM1 peptide (A). Excerpted fragment runs from residues R 23
through T59 to ensure inclusion of full TM1 domain. The fragment was inserted into a pNTAP
vector (B) for introduction of cytomegalovirus promoter and poly-adenosine stabilization
sequence.
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Human aortic smooth muscle cells (HuAoSMCs, Biowhittaker Inc., Walkersville,
MD) were cultured in smooth muscle cell basal medium supplemented with fetal
bovine serum (5%), human recombinant epidermal growth factor (hEGF; 0.5
ng/ml), insulin (5 g/ml), human recombinant fibroblast growth factor (hFGF; 2
ng/ml) plus gentamicin (50 g/ml), and amphotericin-B (50 ng/ml) (all supplies via
Lonza, Allendale, NJ). HuAoSMCs of passages 5–9 were used in experiments.

Transient transfection of cell lines
Transient transfections of HEK 293 cells were initially performed using FuGENE
6 (Roche Applied Science, IN) following manufacturer’s instructions (123). After
discontinuation of FuGENE 6 production, transfections were performed using XtremeGENE 9 (Roche Applied Science, IN), following manufacturer’s
instructions. This replacement reagent was created by Roche as an improved
form of FuGENE 6 with reduced cytotoxicity and the need for less reagent per
transfection. The serum-free medium used in transfections was Opti-MEM
medium (Invitrogen). DNA transfected ranged widely, based on the needs of the
given experiments, but always following the proscribed DNA:transfection
reagent:Opti-MEM medium ratio provided in the literature from the manufacturer.
Exact amounts of DNA transfected varied, based on the assay to be performed
and quantity of cells needed, and are noted in subsequent sections below.
Transient transfections of Meg-01s were performed by nucleofection using an
Amaxa NucleofectorTM II and NucleofectorTM Kit C (Lonza, NJ), per the
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manufacturer’s instructions, introducing a total of 3 μg of DNA to the cells as
instructed. The range of DNA quantities used in HEK 293 transfection was not
possible given the constraints of the nucleofection system. Experimental design
with transfected Meg-01 cells was adjusted based on this constraint, dictating
how many duplicate measurements or treatment groups were possible in a given
replicate.
In all cases, DNA levels were equalized in all transfections using empty pcDNA3
vector. Assays were performed 48 hours after transfection.

Bioluminescence Resonance Energy Transfer (BRET) assay: original
protocol.
Dimerization of rLuc and YFP fused receptors was examined by measuring
bioluminescence resonance energy transfer (BRET) from an energy donor (rLuc
fused) receptor to an energy acceptor (YFP-fused) receptor following addition of
substrate for rLuc (coelenterazine h; Molecular Probes, Life Technologies, NY)
(Figure 5). Coelenterazine h was supplied solid, 250 µg, and stored at -20°C. A
stock vial, in which the compound was resuspended to a 2.5 mM solution in 200proof ethanol, was maintained for further dilution into a working solution (50 μM)
for the assay.
In BRET saturation experiments, cells were transfected with a fixed amount of
rLuc-receptor (0.25µg) together with increasing amounts of YFP receptor
(0.125µg to 1.75µg). Experiments in which the two receptors were capable of
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Figure 5: Illustrated summary of Bioluminescent Resonance Energy Transformation
(BRET) methodology. The underlying mechanism of the BRET assay rests on the short
distance between the two protomers (A and B, above) of a dimeric pair, which brings the
donor, Renilla luciferase (rLuc), and receptor, yellow fluorescent protein (YFP), tags into
close proximity. Coelenterazine activates the rLuc enzyme, producing light with a peak
emission of 475 nm. When no dimerization occurs (left), the distance between rLuc and YFP
is too great to initiate resonance energy transfer, producing a spectrum as shown. However,
when the A and B interact closely, such as during dimer formation, then energy emitted by
rLuc is transfered to YFP, which emits light at a peak of 525 nm, generating the combined
spectrum pictured on the right. Measurement of emissions at 485nm and 550nm (as shown)
allows for quantification of BRET, calculated as the ratio of the emission at 550 over the
emission at 485 corrected for BRET signal background as calculated from untransfected
cells.
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dimerization resulted in a characteristic saturation curve (Figure 6A) that allowed
for calculation of the BRET50 - the level of acceptor receptor YFP-rLuc tagged
receptor (expressed as fold over basal total YFP, excited with an external light
source; see details below) at which half of the maximal BRET signal was
detected.
The BRET50 served as a quantitative measurement of affinity for dimerization,
with a lower BRET50 indicating a higher affinity for dimerization. This allows for
comparison of affinities between receptor pairings. Changes in the maximal
BRET values may reflect absolute levels of dimer formed. However, the absolute
BRET value also can be influenced by the distance and orientation of the donor
and acceptor molecules, which are variable based on the molecular arrangement
of a particular dimer, rather than simply the number of dimers formed. Similarly,
binding of a ligand to either protomer can change the three-dimensional structure
of a receptor, potentially changing the distance between the rLuc donor and YFP
acceptor molecules and, thus, the absolute BRET values. This possibility is
discussed further in the relevant section of the results. Thus, the BRET 50 is
particularly useful as a readout of dimerization affinity that is independent of
changes in donor-acceptor distance.
In BRET competition assays, increasing amounts of a competitor receptor
(without a donor or acceptor moiety) were co-transfected together with a fixed
ratio (1:7) of receptor-rLuc + receptor-YFP (and hence a fixed BRET value). A
reduction in BRET signal as the competing receptor levels are increased
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Figure 6: Indicative responses from BRET assays. Simulated responses from the BRET
assays. (A) A robust, saturable response seen in the BRET saturation assay in response to
increasing concentration of acceptor-tagged receptor indicates a dimerization between the
two receptors of interest. (B) A muted, linear response is obtained from BRET occurring
through random, proximity-based interactions for non-dimerizing species. (C) Loss of BRET
response upon introduction of increasing amounts of non-reporter-tagged receptor is
indicative of dimerization between the untagged competitor and at least one of the reportertagged receptors while (D) no loss of BRET signal indicates that the untagged receptor lacks
sufficient affinity for dimerization with either tagged receptor.
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indicates that the competing receptor can interact with either (or both) protomer,
allowing an initial characterization of dimerization affinity (Figure 6C). This assay
is useful for initial screen of receptor pairings of interest, as it does not require
the time-consuming work of stop codon removal generation of donor and
acceptor fused proteins.
Initially, BRET measurements were performed following protocols published by
Bouvier, et al. (121). Forty eight hours after transient transfection, cells were
harvested (phenol red-free Hank’s Balanced Salt Solution containing 0.02%
EDTA), washed twice with phosphate-buffered saline and resuspended in DPBS
containing 5.56 mM glucose (Invitrogen, 14287), then redistributed in two 96-well
plates (first: black, clear-bottomed; second: white, opaque-bottomed; 100,000
cells/well) and maintained at 37°C. Total YFP (Ex485nm, Em555nm) was first
collected using a luminescence multi-plate reader (VICTOR3, Perkin Elmer) with
the black, clear-bottomed plate and acceptor expression calculated as fold over
basal. Following this, coelenterazine h (Invitrogen, stock resuspended to 2.50
mM in ethanol for working solution) was diluted to 5μM in phosphate buffered
saline containing Ca2+ and Mg2+. A fresh solution was made each time, added to
all cells in the white plate, and emission from the donor (485nm) and acceptor
(555nm) were gathered sequentially from each well across the entire plate. Milli
BRET units (mBU) were calculated as the ratio of Em555 over Em485 nm
corrected for cells expressing the rLuc receptor alone, and arbitrarily multiplied
by 1000.
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BRET assay optimization
After several months of using this standard approach, concerns surfaced as to
the stability of the BRET signal over the time taken to process a single plate (i.e.
from the time of substrate addition to the time of the last BRET reading, typically
20 minutes). A simple experiment was designed to examine signal stability: a
single population of HEK 293 cells were transiently transfected with a set ratio
(1:7) of rLuc- and YFP-tagged TP and the established protocol used to
establish whether YFP and BRET readings were consistent across both plates.
Total YFP values were stable across the black plate; however, the BRET signal
was strikingly unstable (Figure 7, Figure 8), with a significant loss of signal. This
loss of signal across a homogenous plate raised concerns for interpretation of
the BRET assay going forward.
A variety of different experimental adjustments were made in attempts to
minimize the loss of BRET signal observed with the original assay protocol: [1]
the protocol was amended to take a reading of one sample set (6 replicates) from
the black total YFP plate followed by one reading from the white BRET plate,
alternating so as to more closely align the time of measurement of the two values
for a given sample. [2] 2-hydroxypropyl-β-cyclodextrin, a ring-shaped compound
that increases solubility and stability of compounds in water (158), was added to
the coelenterazine solution in an attempt to stabilize the substrate over the time
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Figure 7: Signal loss inherent in the original BRET methodology. Over the course of the
nearly 20 minutes required for sequential measurement of emissions at 485nm and 550nm, a
steep drop in the raw values, by approximately two thirds, was noted. This raised significant
concerns of increased noise as the signal drops towards the limit of detection.
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Figure 8: Decay in BRET and component emissions over time. HEK 293 cells
were transfected with rLuc- TPWT (donor, 0.25µg) + YFP- TPWT (acceptor, 0.75µg).
Two 96-well plates were prepared containing identical samples in each well (except
for the control rLuc alone cells), and assayed following the original BRET protocol:
2+
coelenterazine was diluted to 50 μM in PBS containing Ca immediately prior to
distribution into all 96 wells, with the full plate (white opaque bottom) read at one
sitting. Total.YFP emission was measured separately in the second plate (black,
clear bottom). A representative experiment is shown. Emission at both 485nm and
550nm decreased over a full order of magnitude (top), while BRET values decayed
from 125 mBu to 50 mBu (bottom).
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taken to perform the readings. Neither adjustment improved the signal stability
across a homogenous set of plates.
A search of data sheets and technical literature for coelenterazine h as a
substrate for Renilla luciferase revealed (159) that coelenterazine undergoes a
predictable deterioration upon introduction to aqueous solution with a 40-50%
loss of functional capacity over the first 20 minutes. After this period has passed,
however, the solution maintains a mostly linear functional response over the next
four hours (Figure 9). Additionally, this decay appears to be caused in part by the
presence of calcium cations in solution. Based on this information, the BRET
assay was modified to include [3] a 20-minute waiting period at room
temperature after addition of the coelenterazine into Ca2+-free phosphate
buffered saline before addition to the wells.
Because of the time taken from the first addition of colenterazine to the final
reading of the 96th well (20 min), loss of signal due simply to substrate catabolism
by rLuc was a further issue. One approach to addressing this issue was imaging
of the whole plate at one time through use of an IVIS imaging system. Luciferase
and YFP activity was captured for the plate as a whole, and binning (manually
overlaying a 96-square grid onto the image produced by the IVIS so as to allow
quantitation of activity by well) was employed to measure the YFP and BRET
signals given off by samples. This proved significantly less sensitive that the
Victor multiwell plate reader. However, a significant observation was made in the
course of the imaging trials: the white, opaque plate used in the BRET assay
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Figure 9: Decay of aqueous coelenterazine at 27 °C. Colenterazine ((10
mg/mL; 2.4mM in 200mM NaCl, 50mM Tris, 0.08% (v/v) Triton® X-100, pH
7.8). Measurements were made with EG&G Berthold LB 96V Microplate
Luminometer and integrated over 10 seconds. The fast decay phase (~ 20
min) coincides with the window of time emissions are collected using the
original BRET protocol, thus colenterazine emission will be significantly
lower for wells read last compared to first. (Credit: FluoProbes® technical
sheet)
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itself emitted significant amounts of background light emission during the
measurement. Thus, despite the established protocols calling for the use of two
separate plates for the BRET assay – the clear bottomed black plate for total
YFP and the opaque white plate for BRET, it appeared that it was preferential to
avoid the white plate (hence reducing background) and instead to [4] use a single
clear-bottomed black plate to measure first the YFP signal and then, after
addition of coelenterazine h (rested in Ca2+-free buffer for 20 mins), the BRET
signal. This change to the method had the added benefit of taking paired YFP
and BRET measurements from the exact same sample of cells, as opposed to
two different distributions of the same cell mixed in two parallel plates, further
improving precision (Figure 10).
To avoid loss of signal due to enzymatic substrate catabolism, [5] coelenterazine
was added to one sample (six replicate wells) and the BRET signal was
measured before moving to the next sample. This approach greatly reduced the
time that the substrate sat in the well with the enzyme before the BRET reading.
Altogether, these 5 changes to the assay resulted in a marked improvement in
signal stability across a plate (Figure 11) as well as the following improved
protocol that is now standard in the laboratory:
Coelenterazine h (Invitrogen, stock resuspended to 2.5 mM in 200-proof ethanol
for working solution) was diluted to 5μM in Ca2+- and Mg2+-free phosphate
buffered saline and allowed to rest at room temperature for 20 minutes. Cells
transiently transfected 48 hours prior were harvested (phenol red-free Hank’s
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Figure 10: Decay in BRET and component emission measurements after initial
modifications to BRET protocol. HEK 293 cells were transfected with rLuc- TPWT
(donor, 0.25µg) + YFP- TPWT (acceptor, 0.75µg). Two 96-well plates were prepared
containing identical samples in each well (except for the control rLuc alone cells) and
assayed following a modified BRET protocol: coelenterazine was diluted to 50 μM in
2+
PBS without Ca and allowed to sit for 20 minutes prior to use. Coelenterazine was
distributed into each row separately, and emissions collected row by row immediately
following coelenterazine addition (white opaque bottom). Total YFP emission was
measured separately in a second plate (black, clear bottom). A representative
experiment is shown. Although the drop in emission at 485nm and 550nm was less
that with the original BRET protocol, there was a marked spread in values across each
row (top); the decay in BRET values was also blunted (90 mBu to about 70 mBu;
bottom) but similarly inconsistent across a single row.
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Figure 11: Decay in BRET and component emission measurements after final
modifications to BRET protocol. HEK 293 cells were transfected with rLuc-TPWT (donor,
0.25µg) + YFP- TPWT (acceptor, 0.75µg) assayed following the a further modified BRET
2+
protocol: coelenterazine was diluted to 50 μM in PBS without Ca and allowed to sit for 20
minutes prior to use. Cells were distributed into a black, clear-bottomed 96-well plate. Total
YFP emission was measured. Coelenterazine was then added to each of the 6 replicate
wells and emissions collected immediately. This process was repeated for each sample
until all samples were read. A representative experiment is shown. Some drop in emission
at 485 and 550 nm was evident, however this was to a much lesser degree that the original
or mid-optimization and there was good agreement for replicate values from each sample
(top). Further, BRET values decayed slightly from 125 mBu to about 110 mBu over the first
500 seconds but remained steady for the rest of the assay (bottom).
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Balanced Salt Solution containing 0.02% EDTA), washed twice with phosphatebuffered saline and resuspended in DPBS containing 5.56 mM glucose
(Invitrogen, 14287), then redistributed into a black, clear-bottomed 96-well plate
(100,000 cells/well) and maintained at 37°C. Total YFP (Ex485nm, Em555nm)
was first collected using a luminescence multi-plate reader (VICTOR3, Perkin
Elmer) and calculated as fold over basal (no YFP-fused receptor present).
Following this reading, coelenterazine h was added a set of six replicate wells
and donor (485nm) and acceptor (555nm) emissions gathered sequentially for
each sample. Colenterazine addition and BRET readings in sets of 6 replicate
wells were repeated until all data was collected. Milli BRET units (mBU) were
calculated as the ratio of Em555 over Em485 nm corrected for cells expressing
the rLuc receptor alone, and multiplied by 1000.

Cell surface expression of the TP
HEK 293 and Meg-01 cells were transfected with HA-tagged TPWT or HATPL205,L209,Y213. Cells were harvested into ice-cold FACS buffer (DPBS containing
1% BSA and 0.1% sodium azide). Cell suspensions were stained with anti-HA
mouse IgG1 (Monoclonal 16B12) conjugated to Alexa Fluor® 488 (Invitrogen,
CA) for 30 minutes prior to washing. Median fluorescence intensity (MFI) was
collected using a BD FACSCalibur flow cytometer (Becton Dickinson, Franklin
Lakes, NJ, maintained by UPenn flow cytometry core). Cells were first gated to
include only live cells of the proper size in the measurement via forward and side
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scatter measurements, then gated on the FL1 filter (488nm excitation, 530/30nm
filter emission) to obtain MFI values, which were corrected by subtraction of
collected MFI values of non-transfected, antibody-stained HEK 203 of Meg-01
cells.

Measurement of second messenger generation
Measurement of intracellular inositol monophosphate (InosP) or cyclic AMP
(cAMP) was performed using the IP-One Tb kit (Cisbio Bioassays, MA) or
LANCE cAMP 384 kit (PerkinElmer, MA), respectively, according to the
manufacturer’s instructions. Both kits are based around the same principle of
fluorescence resonance energy transfer (FRET) between two fluorophores. In the
IP-One InosP assay, cells are treated with a mixture of [a] monoclonal anti-InosP
antibody (Ab) tagged with crypate (a fluorophore) and [b] InosP tagged with the
dye “d2”, in addition to [c] LiCl, which inhibits inositol-phosphate phosphatase.
The d2-InosP forms a complex with the crypate-Ab that allows for FRET from the
crypate to the d2 upon excitation of the former. Unlabeled InosP, produced by
the cell, competes for binding to the crypate-Ab. The more InosP is produced by
the cell, the less FRET-capable complex is created, with the ratio of light emitted
by the crypate to light emitted by the d2 dye as the quantitative readout of cellular
InosP production after comparison to a standard curve of InosP concentrations.
This same principle is employed by the LANCE cAMP assay, with europiumtagged streptavidin replacing the crypate-Ab, and AlexaFluor-tagged cAMP
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replacing the d2-tagged InosP. IBMX (3-isobutyl-1-methylxanthine) is employed
to inhibit cAMP degradation through phosphodiesterase inhibition. Cells were
stimulated with or without the TP agonist U46619 (Cayman Chemicals, MI) over
a range of concentrations, as noted in the respective results section, for one
hour.

Radioligand binding and displacement
HEK 293 cells, transfected with HA-tagged TPWT or TPL205,L209,Y213 in poly-L
lysine-coated 12 well plates, were washed with radioligand binding buffer (HBSS
with 2% BSA). For saturation binding 3H-SQ 29,548 (PerkinElmer, Waltham, MA
or American Radiolabeled Chemicals, St. Louis, MO) was distributed to cells at
concentrations ranging from 25 μM to 250 μM. After 60 minutes at 37°C, cells
were washed with ice-cold binding buffer to remove unbound ligand, lysed with 1
M NaOH for 30 minutes at 37°C and radioactivity measured by scintillation
counting.
For displacement analysis, 3H-SQ 29,548 was held constant at 0.25 nM and
competing ligands were added 5 minutes prior to the radioligand. Competing
ligands I-BOP and cold SQ 29,548 were applied as treatments ranging from 5 nm
to 500 nm, while U46619 and the isoprostane E2III (iPE2III) concentrations ranged
from 25 nm to 2500 nm, due to lower affinity for the TP. In either experiment,
non-specific binding was accounted for by the addition of a 100-fold excess of
cold SQ 29,548. After 60 minutes at 37°C, cells were washed with ice-cold
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binding buffer to remove unbound ligand, lysed with 1 M NaOH for 30 minutes at
37°C and radioactivity measured by scintillation counting.

Immunoprecipitation and immunoblotting
HA-tagged TPWT or TPL205,L209,Y213 were immunoprecipitated from transfected
HEK 293 cells using Pierce HA Tag immunoprecipitation/Co-immunoprecipitation
Kit (cat# 23610,Thermo Scientific, Waltham, MA), according the manufacturer’s
instructions. This kit uses anti-HA antibody conjugated to agarose beads for
immunoprecipitation of HA-tagged proteins. Eluted proteins were resolved via
NuPAGE electrophoresis (Invitrogen, CA) under reducing conditions. HA-tagged
TPWT or TPL205,L209,Y213 were visualized with anti-TP (Cayman Chemicals, MI;
1:100) while immunoprecipitated Gqα was visualized with anti-Gq/11α (Millipore,
CA; 1:1000). Antigen-antibody complexes were revealed using horseradish
peroxidase conjugated anti-rabbit IgG (Jackson ImmunoResearch, PA; 1:10,000)
and visualized by enhanced chemiluminesence (ECL Plus, GE
Healthcare/Amersham, NJ). Quantification of proteins was by densitometry.

Treatment of cells with the CHAMP peptide
A computed helical anti-membrane protein (CHAMP) peptide (128, 142) was
supplied by the lab of Dr. Joel Bennett (University of Pennsylvania School of
Medicine) as 1 mM CHAMP in DMSO. As directed by members of the Bennet
lab, the treatment concentration of 1 μM CHAMP was employed in BRET and
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second messenger generation assays. To avoid vehicle effects, the total final
concentration of DMSO in media did not exceed 0.1%.

Quantitative-PCR
RNA isolated from human aortic smooth muscle cells grown in culture was
quantified (NanoDrop Spectrophotometer) and reverse transcribed into cDNA
(MultiScribe Reverse Transcriptase, Applied Biosystems) according to
manufacturer’s instructions. Quantitative real-time polymerase chain reaction (QPCR) was carried out using inventoried primer/probe gene expression assays
with TaqMan Universal PCR Master Mix (Applied Biosystems) for the human
thromboxane receptor gene (TBXA2R, cat# 4331182). Q-PCR products were
monitored using the ViiaTM 7 Real-Time PCR System (Applied Biosystems) and
data was analyzed using the 2-ΔΔCt method of relative quantification (RQ) using
18S for normalization (160).

Receptor modeling
Working with the Hwa Laboratory (Yale Medical School), the human hTP
sequence was aligned with solved crystal structures, bovine rhodopsin (OPSD,
UniProt identifier P02699) and the human ß2-adrenergic receptor (ADRB2,
UniProt identifier P0755) in ClustalW [http://www.clustal.org]. Both the PAM250
and BLOSUM evolution matrix modeling algorithms (161) indicated closer
alignment of hTP to align more closely with OPSD (similarity score 30.16) than
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with ADRB2 (33.48). Each bundle of seven transmembrane -helices was
therefore based on a 2.8Å crystallographic bovine rhodopsin template (1HZX)
(162) using the internet-based protein-modeling server, SWISS-MODEL
[http://swissmodel.expasy.org] (GlaxoSmithKline, Geneva, Switzerland), and
energy minimized using the Gromos96 force field in DeepView [http://spdbv.vitalit.ch]. Extracellular and cytoplasmic loop regions were manually constructed, built
according to JPred consensus, and energy-minimized using the NAMD molecular
dynamics simulator (163).

Fluorescence microscopy
HEK 293 cells were grown to 80-90% confluency in 60 mm dishes, then lifted in 1
mL 0.25% trypsin, then added to 8 mL HEK growth medium. Cells were
transfected in 0.4 mL aliquots by 0.25 μg of either myc-TPWT or mycTPL205,L209,Y213, with each aliquot being dispensed into one well of an 8-well polyD-lysine-coated slide (Becton Dickinson, Franklin Lakes, NJ) and allowed to
grown for 48 hours. Cells were then fixed with 4% paraformaldehyde for 10
minutes at room temperature, followed by permeabilization with 0.2% Triton X100 in PBS. Staining was performed with 1:800 diulted anti-myc AlexFluor 555
conjugate (Millipore, Billerica, Massachusetts) for one hour with gentle shaking.
Cells were then mounted with Vectashield + DAPI (VectorLabs, Burlingame, CA)
and cover slips were sealed with clear nail polish. Imaging was performed on a
Zeiss Widefield Microscope at 40x magnification.
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CHAPTER 3: Characterization of Thromboxane Receptor Regulation.

TPα auto-upregulation is not driven by increases in mRNA levels
The first possibility explored as a mechanistic explanation for auto-upregulation
of the TP following agonist activation (70) was increased receptor biogenesis
resulting from elevated levels of mRNA. If one downstream effect of TP activation
was to increase TP mRNA levels this could contribute to the increase in TP
protein and cell surface TP levels observed. To examine whether TP activation
leads to increases in mRNA levels TP-transfected HEK 293 cells or human
aortic smooth muscle cells (HuAoSMCs), which endogenously express TP, were
treated with either 100 nM IBOP, 1 μM SQ 29,548 (a TP antagonist), or a
combination of both for 2 hours. Cells were harvested and TP mRNA quantified
by real-time PCR. IP mRNA was also measured as a negative control since IP is
not stimulated by IBOP. Quantitative comparisons made to mRNA levels at pretreatment showed no significant change in mRNA levels for cells with any
treatment (Figure 12). Thus, upregulation of TP transcription in response to
short-term agonist treatment did not appear to contribute to auto-upregulation.
Additional studies were performed to query whether a longer-term agonist
treatment could lead to changes in mRNA levels that might explain that autoupregulation paradigm. In both transiently transfected HEK 293 cells as well as
natively expressing HuAoSMCs, 6- or 12-hour treatment with 100 nM IBOP lead
to no significant change in TPα mRNA levels (Figure 13A, B). Nor did we see any
change in mRNA levels in HuAoSMCs treated with 1 μM IBOP over a time
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(A)

(B)

Figure 12: Levels of TP and IP mRNA after a 2-hour IBOP treatment. TP mRNA
levels were measured by real time PCR. Human aortic smooth muscle cells were
treated 100 nM IBOP, 1 μM SQ 29,548 (a TP antagonist), or a combination of the
two, for 2 hours prior to harvest and quantification of TP, IP, and 18S mRNA.
mRNA expression for both TP and IP is reported as a ratio of receptor mRNA
present at the given time to mRNA at time zero, corrected for 18S. No significant
difference was evident for any treatment in either TP or IP mRNA levels. Data are
mean ± standard error of n=3.
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(A)

(B)

(C)

Figure 13: Activation of the TP does not alter TP transcription.
HEK 293 cells transiently transfected with TPα (A) or HuAoSMCs (B,
C) were serum starved for 24 hours before IBOP treatment. Total
RNA was extracted and reverse transcribed into cDNA, and TP
expression was examined by real-time PCR. Values were normalized
to either β-actin or 18S levels and are expressed as the fold change
compared with control (no IBOP). Data are mean ± SEM (n = 3–5).
ns, nonsignificant compared to control.
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course of up to 24 hours (Figure 13C). Thus, agonist activation in both and the
long and short terms did not cause any noticeable changes in mRNA levels that
could explain the auto up-regulation seen for the TPα.

A modified version of the BRET assay provides greatly increased
sensitivity
Preliminary co-immunoprecipitation studies carried out previously in the lab
suggested that, similar to other GPCRs (100–103, 107, 114, 115), the TP formed
homodimers within the cell. To address the question of dimerization in live cells
(as compared to the cell homogenates used in co-immunoprecipitation assays),
we used the bioluminescence resonance energy transfer (BRET) assay, which
measures transfer of energy from a donor (rLuc-fused receptor) to acceptor
(YFP-fused receptor) as their physical interaction (for details see Chapter 2,
Methods, Pages 26-30 and Figure 6). As outlined in Chapter 2 (Pages 31-39),
while establishing the BRET assay, we noticed a large decline in the raw values
for the emission readings from the beginning to end of reading the BRET plates.
We considered whether this decline in signal was a real reflection of changing
dimerization events or indicative of potential problems with the design of the
BRET assay itself. To examine this, one large, homogenous batch of cells were
transfected with a set amount of TP-rLuc and TP-YFP. These cells were
harvested, then resuspended in DPBS with glucose and sodium pyruvate, then
plated in all 96 wells of the plate, as per the original BRET protocol.
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Coelenterazine h (rLuc substrate) was added to all wells, and the plate was read
as a whole (approximately 20 min from start to finish). Rather than the expected
equivalent signals from all wells, the rLuc emission signal (read at 485 nm)
decreased dramatically from 10,000 to less than 1,000 (arbitrary units), while the
YFP emission signal decreased from approximately 5,000 to under 500 (arbitrary
units). Of particular concern, the BRET signal itself decreased from 120 to 50. As
described above (Chapter 2, Figure 11), the BRET assay was rigorously
assessed and optimized to avoid these possible confounding issues with the
original protocol. First, we discovered that coelenterazine decomposes
significantly during the first 20 minutes after introduction to aqueous solution,
particularly in solutions containing calcium. Thus the protocol was changed to
used Ca2+- and Mg2+-free DPBS for coelenterazine dilution and to include a 20
minutes rest period prior to use. Second, to minimize loss of substrate by rLuc
metabolism during the significant “down-time” between coelenterazine addition
and emission collection, samples were stimulated and read immediately as
separate 6-well groups (a single sample with 6 replicate measurements). With
these modifications, signal loss was significantly improved to 30,000 to 20,000
for rLuc and 18,000 to 11,000 for YFP across a representative plate. Additionally,
BRET signal only decayed from 130 to 110 across the plate and was steady after
the first 500 seconds.

Dimerization of the TP occurs with TP, IP, and DP1, but not CCR5
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HEK 293 cells were transiently transfected with rLuc- (donor, 0.25µg) plus YFP(acceptor, 0.125µg – 0.75µg) fused pairings of TP-TP. We confirmed that the
TP does undergo homodimer formation within living cells with an affinity that
suggests physiological occurrence of dimerization (Figure 14). Previous work in
the lab also demonstrated co-immunoprecipitation of TP with the IP, thus we
also examined this association by BRET. In HEK 293 cells transiently transfected
with rLuc- (donor, 0.25µg) plus YFP- (acceptor, 0.125µg – 0.75µg) fused pairings
of TP-IP BRET was saturable and occurred at a similar affinity to TP-TP
indicating equal propensity for the TP homodimer and TP-IP heterodimer to
form (Figure 15A). A concern in the field of GPCR dimerization is that overexpression of any two GPCRs will lead to some level of interaction providing a
“false positive” for dimerization. Thus, it is important to define a negative control
(a non-interacting receptor). We examined two GPCRs as non-interacting
receptor controls, the PGD2 receptor DP1 (121) and chemokine receptor CCR5.
TP-DP1 or TP-CCR5 dimerization was assessed using the BRET assay.
Interestingly, TP formed a heterodimer with DP1, but this was at a significantly
lower affinity compared to TP-TP and TP-IP (Figure 15B). This suggests that, in
a physiological setting, the TP could dimerize with the DP1, potentially modifying
the function of either or both partners, but the TP-TP and TP-IP dimers are likely
to out-compete the TP-DP1 dimer. It is possible that the TP-DP1 heterodimer is
more relevant in situations where DP1 is present at a higher relative
concentration compared to the TP and/or IP, or under conditions of agonist
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rLuc-TPWT +
YFP-TPWT

Figure 14: Homodimerization of TPWT by BRET. Saturable BRET was observed for
rLuc- (donor, 0.25µg) + YFP- (acceptor, 0.125µg – 0.75µg) fused pairings of TPWTTPWT in transiently transfected HEK 293 cells. Representative experiment is shown.
Data are milli BRET units plotted against fold over basal total YFP emission (a
measure of YFP-fused acceptor receptor expression). The BRET50 value for this
experiment is indicated by the dotted gray line.
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(A)

(B)

rLuc-IP +
YFP-TPWT

rLuc-TPWT +
YFP-DP1

(C)

(D)
rLuc-CCR5 +
YFP-TPWT

Figure 15: Heterodimerization of TPWT by BRET. Saturable BRET was observed for rLuc(donor, 0.25µg) + YFP- (acceptor, 0.125µg – 0.75µg) fused pairings of (A) TPWT-IP and (B)
TPWT-DP1 in transiently transfected HEK 293 cells. No saturable BRET was observed for
(C) rLuc- TPWT (donor, 0.25µg) + YFP- CCR5 (acceptor, 0.125µg – 0.75µg) in transiently
transfected HEK 293 cells. Representative experiments are shown. Data are milli BRET
units plotted against fold over basal total YFP emission (a measure of YFP-fused acceptor
receptor expression). Individual BRET 50 values for each representative experiment are
indicated by the dotted gray lines. (D) BRET 50 values were calculated from 4-6 individual
BRET saturation experiments. Data are mean BRET 50 values ± SEM from n=4-6.
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activation or other cell or context-specific settings. These are intriguing questions
that remain to be experimentally examined. Importantly, there was no evidence
for dimerization of the TP with CCR5, arguing against a non-specific interaction
between any two GCPRs expressed in the same cell (Figure 15C).

Dimerization does not contribute to auto-upregulation of the TP following
agonist activation.
Studies report that dimerization is essential for normal biogenesis of GCPRs
(109, 114, 115, 164). Thus, having shown that TP homodimerization does occur,
we considered whether agonist-induced modulation of TP homodimerization
might contribute to augmented receptor stability and membrane expression,
providing a post-translational mechanistic explanation for auto-upregulation of
the agonist-stimulated TP. To examine this possibility, cells were treated with
IBOP, a TxA2 mimetic, prior to analysis of TP homodimerization by BRET.
However, there was no significant change in maximal BRET or BRET50 (Figure
16A). We and others reported that auto-upregulation of TP is dependent on a
reactive-oxygen species mechanism and replicated by treatment of cells with
H2O2 (70, 165). Thus we examined whether H2O2 treatment modified TP
homodimerization. Similar to IBOP treatment, however, there was no significant
effect of H2O2 on TP homodimerization by BRET assay (Figure 16B).
These experiments that were designed to address how agonist activation of a
receptor modifies its dimerization raised interesting questions that have been
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(A)

(B)

Figure 16: Impact of agonist treatment on TPα homodimerization.
Saturable BRET was observed for rLuc- TPWT (donor, 0.25µg) + YFPTPWT (acceptor, 0.125µg – 0.75µg), with or without (A) 100 nM IBOP
(6hr) or (B) 1uM H2O2. No significant change was seen in either BRET max
or BRET50. Data are mean ± standard error of n=3.
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considered by other GPCR labs but not formally addressed: does ligand
treatment modify BRET independent of true changes in absolute dimer levels?
Since resonance energy transfer is dependent on the close proximity of the
donor and acceptor molecules, and the magnitude of this distance determines
the efficacy of the energy transfer, then it stands to reason that shifts in the
conformation of the partners in a dimeric arrangement could induce a change in
the distance or orientation between the pair of signaling molecules. Such a
conformational change is commonly accepted as necessary for propagation of
agonist-induced signaling to downstream effector molecules. Thus, the treatment
of a dimer with an agonist (or any other ligand that causes conformational
changes) to either or both of the protomers could impact the BRET signal but not
reflect a change in dimerization per se, leading to a false positive for liganddependent dimerization. To study the possibility of this occurring in the TP
dimerization assay, HEK 293 cells were transfected with rLuc- (donor, 0.50µg) +
YFP- (acceptor, 1.00µg ) fused pairings of TPWT-TPWT, then treated with either
agonist (100 nM IBOP), 1uM SQ 29,548 (antagonist), or both for 10 minutes prior
to BRET analysis. Maximal BRET after treatment with combined SQ 29,548 and
IBOP was significantly lower than that of untreated cells (*p<0.05) (Figure 17).
While the change seen in this assay was small, it suggests that ligand and
conformational changes binding can impact assay readout making the BRET
assay less suitable to study agonist-induced modulation of TP dimerization.
Thus, although our studies did not support the hypothesis that TP dimerization
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Figure 17: Effect of ligand treatment on maximal BRET values in TPWT
homodimerization. HEK 293 cells were transfected with rLuc- TPWT (donor, 0.50µg) +
YFP- TPWT (acceptor, 1.00µg) then treated with either 100 nM IBOP, 1uM SQ 29,548, or
both for 10 minutes prior to BRET analysis. Maximal BRET after treatment with
combined SQ 29,548 and IBOP was significantly lower compared to untreated cells
(*p<0.05). Data are mean ± standard error of n=3.
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contributes to its auto-upregulation, this possibility still exists and could be
examined through use of an assay that lacks these potential limitations of the
BRET assay.
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CHAPTER 4: Targeting the Specific GGL Motif of the TP as a Means of
Receptor Regulation

Identification and mutation of a GxxxGxxxL motif in the 5th transmembrane
of the TP
Analysis of the TP amino acid sequence revealed a GxxxGxxxL motif in TM5:
G205LSVG209LSFL213 (see Figure 1). Additional GxxxG motifs were identified
toward the N-terminus (G5SSLG9), within the 1st intracellular loop (G51ARQG55)
and 2nd extracellular loop (G188AESG192). Given that a TM GxxxGxxxL motif has
been implicated in the functioning of at least two GPCRs (104, 115), and that
transmembrane domains have been noted for their involvement in dimerization
(126, 127), we chose to focus further on the G205LSVG209LSFL213 domain. Threedimensional homology modeling of the TP revealed an outward-facing orientation
of G205, G209 and L213 (see Figure 3) in TM5 indicating that this domain is
appropriately positioned for protein-protein interaction within the membrane. To
define the functional relevance of the TM5 GxxxGxxxL motif in the TP we
employed site-directed mutagenesis to replace G205 and G209 with leucines and
L213 with a tyrosine to generate TPL205,L209,Y213. As outlined previously (Chapter 2,
Constructs, Pages 21-22), we replaced G205 and G209 with leucines, a small-tolarge replacement that disrupts helix-helix interaction (139, 141, 142), and
replaced L213 with a tyrosine based on the studies of the GxxxGxxxL motif in the
ß2-adrenergic receptor (115). Mutagenesis was carried out via polymerase chain
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reaction and using primers designed with a modified sequence for the residues of
interest (Table 1). The mutations were added sequentially, with verification of the
target sequence prior to introduction of the next mutation.

Disruption of the TM5 GGL motif suppressed TP function
Having successfully introduced mutations into the G205xxxG209xxxL213 motif, we
examined the impact on TP function. We first measured the ability of the wild
type TPWT and TPL205, L209, Y213 to transduce a signal via the canonical
phospholipase C/inositol phosphate pathway in response to the thromboxane
mimetic U46619. In transiently transfected HEK 293 cells, the maximal signaling
capacity of TPL205, L209, Y213 was significantly reduced by ≈25% compared to TPWT
transfected cells, although there was no significant change in EC50 (Figure 18A).
We also examined signaling of the mutant receptor in the Meg-01 cell line. Meg01 cells are megakaryoblasts derived from a chronic myelogenous leukemia line
(166). When grown in culture, adherent Meg-01s can be nucleofected leading to
the release of daughter cells into suspension that express the construct of
interest. These daughter cells are platelet-like cells, thereby serving as a closer
approximation to the TP’s native environment. Depressed signaling via the
TPL205, L209, Y213 was also evident in Meg-01 cells (Figure 18B), with a ≈50%
reduction in inositol phosphate generation and a significant rightward EC50 shift.
Thus, disruption of the TM5 GxxxGxxxL motif markedly suppressed TP response
to agonist.
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(A)

(B)

Figure 18: Inositol Phosphate Signaling through WT and mutant TP.
(A) Maximal inositol phosphate (InosP) generation was reduced by 25 ± 5%
(p<0.0001) in TPL205,L209,Y213 (open circles) compared to TPWT (closed
circles) transfected HEK 293 cells. There was no significant change in
EC50. (B) Maximal InosP generation was reduced by 50 ± 7% (p<0.01) with
a significant rightward shift in EC50 (p<0.05), in TPL205,L209,Y213 (open circles)
compared to TPWT (closed circles) transfected Meg-01 cells. Data are % of
maximum response (in TPWT) and are mean ± sem; n=4-6.
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We next sought to define how mutation of the G205xxxG209xxxL213 motif reduced
TP signaling. We considered the various stages along the biogenic and signaling
pathways that could be impacted by the introduction of such a mutation. For
example, disruption of this motif could lead to protein misfolding in the ER,
possibly causing ER retention through failure at a dimerization-dependent
checkpoint (115). Alternatively, the mutant receptor may be processed and
expressed normally but disruption of helical interactions via the TM5 GxxxGxxxL
motif could lead to loss of ligand binding, because of possible changes to the
ligand-binding pocket or G protein interaction, thereby disrupting signal
transduction in response to agonist. Finally, even if the receptor maintained
normal ligand binding and normal communication with downstream effectors,
disruption of the TM5 GxxxGxxxL helical interaction motif may interfere with
normal dimerization with a consequent failure of proper interaction between the
protomers and suppressed signaling. These possibilities were examined in turn.

Disruption of the TM5 GGL motif did not reduce TP cell surface expression
First, we examined whether the loss of TPL205, L209, Y213 signaling reflected simply
reduced cell surface expression of the mutant receptor. By confocal microscopy
of HEK 293 cells transiently transfected with HA-tagged TPWT or TPL205,L209,Y213,
we observed qualitatively similar subcellular distribution of the mutant compared
to WT (Figure 19), suggesting that loss of the TM5 GxxxGxxxL motif does not
cause a change in retention of the receptor in the ER, or altered distribution in
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A

B

Figure 19: Cellular localization of TPWT or TPL205, L209, Y213 mutant.
HEK 293 cells were transiently transfected with either TPWT or TPL205,
L209, Y213, tagged at the amino terminus with a c-myc epitope tag.
Receptor localization was examined by immunofluorescence
microscopy in cells stained with fluorophore-tagged antibody against
the relevant epitope tag [AlexaFluor 555-anti-myc] and nuclei stain
[4,6-diamidino-2-phenylindole (DAPI), blue stain], 40x magnification.
Images are from a representative experiment that was repeated with
similar results.
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other areas of the cell. As is typical for transiently transfected GPCRs expressed
under a constitutively active promoter, plasma membrane receptor expression
was not clearly distinguished by immune fluorescence microscopy. To
quantitatively establish disruption of the TM5 GxxxGxxxL motif altered membrane
localization of receptor we examined cell surface expression of the TPWT or
TPL205, L209, Y213, both tagged at their N terminus with the HA epitope tag, by flow
cytometry. In both transfected HEK 293 or Meg-01 cells there was no significant
difference in cell surface receptor levels, as measured by median surface HA
fluorescence intensity, between TPWT and TPL205, L209, Y213 transfectants in either
cell type (Figure 20). Thus, disruption of the TM5 GxxxGxxxL motif did not
appear to substantially modify receptor processing to the surface, indicating that
the signaling deficit we observed could not be explained by quantitative changes
in the receptor population on the plasma membrane leading to reduced exposure
to ligand.

Ligand affinity and is not modified by mutation of the TM5 GxxxGxxxL
motif
Second, we addressed the possibility that loss of the TM5 GxxxGxxxL motif
might cause a conformational shift changing the TP ligand-binding domain
thereby reducing agonist affinity for TPL205, L209, Y213 and suppressing signal. Intact
HEK293 cells expressing either TPWT or TPL205, L209, Y213 were labeled with a
single concentration of 3H-SQ 29,548 and displacement examined for two TP
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(A)

(B)

Figure 20: Surface Expression of Wild Type and Mutant TP. (A) HEK 293 cells or (B) Meg-01
cells were transfected with N-terminal hemagglutinin (HA)-tagged TPWT or TPL205,L209,Y213 and
surface HA quantified by flow cytometry as a measure of surface receptor expression. Left panels
show representative histograms, taken at one sitting using identical settings; right panels show the
median fluorescent intensities (mean ± SEM, n=7). There was no significant difference in surface
expression of TPWT vs TPL205,L209,Y213 in either cell model.
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agonists, U46619 (Ki=90nM for TPWT vs. 52nM for TPL205, L209, Y213) and IBOP
(Ki=1.8nM for TPWT vs. 2.5nM for TPL205, L209, Y213), or by unlabelled SQ 29,548
(Ki=4nM for both TPWT and TPL205, L209, Y213) as a reference. No significant
difference in displacement was evident between the wild type and mutant
receptors. We also examined an isoprostane, iPE2III (Ki=334nM for TPWT vs.
403nM for TPL205, L209, Y213), a free radical-generated metabolite of arachidonic
acid that can activate the TP in vivo (24), and again saw no difference in
radioligand displacement (Figure 21). Further, in 3H-SQ 29,548 in saturation
binding analysis (Figure 22), although saturation was not reached because of
issues with 3H-SQ 29, 548 solubility, there was no apparent different between the
TPWT and TPL205, L209, Y213. Thus, disruption of the TM5 GxxxGxxxL motif did not
appear to alter the receptor’s ligand binding properties and reduced affinity of
agonist could not explain suppressed signaling.

Association of TP with Gq is not modified by mutation of the TM5
GxxxGxxxL motif
Third, we considered whether disruption of the TM5 GxxxGxxxL motif interferes
with the association of the TP to its effector, Gq, leading to suppressed signaling.
Previous studies of GPCRs, particularly with Gs coupled receptors, have noted
that association of the G protein with the receptor in the inactive, non-ligandbound conformation provides a high affinity state for agonist (167, 168). Such indepth studies have not been reported for Gq- coupled receptors, like the TP,
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(B)
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Figure 21: Displacement of H-SQ 29,548 by Various Ligands. Displacement of H-SQ 29,458
(TP antagonist) by SQ 29,548, the TP agonists U46619 or I-BOP or the isoprostane iPE2III in HEK
293 cells transiently transfected with TPWT (closed circles) or TPL205,L209,Y213 (open circles). Data
are expressed as % of total binding (no displacer) and are mean ± SEM (n=3-8). No significant
change in Ki values for displacement between TPWT and TPL205,L209,Y213 was seen for any TP
ligands used.
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Figure 22: Binding of H-SQ 29,548 to whole cells. Binding of H-SQ 29,458 (TP
antagonist) to whole HEK 293 cells transiently transfected with TPWT (black
squares) or TPL205,L209,Y213 (grey circles). Data are expressed as fmol of bound
antagonist and are mean ± SEM (n=5). No change seen in SQ 29,548 binding
between TPWT and TPL205,L209,Y213 was seen up to maximum possible concentration
(based upon solubility constraints).
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however it is likely that a similar paradigm for the high affinity receptor state
applies. In the radioligand displacement analyses discussed above, we included
two TP agonists: U46619 and IBOP. The lack of difference in the Ki’s for both
agonists argues against a reduction in the affinity state of TPL205,L209,Y213 for
agonist, and thus against modified Gq as an explanation for suppressed signaling
of the mutant.
To confirm normal Gq association of the TPL205, L209, Y213, we performed coimmunoprecipitations in HEK 293 cells transiently transfected with either HAtagged TPWT or HA-tagged TPL205,L209,Y213. Cells were lysed and passed over
anti-HA tagged agarose beads, then probed with either anti-Gq antibody, or antiTP antibody to determine the relative levels of TP within the samples. We
observed that comparable levels of Gq co-immunoprecipitated with either TPWT or
TPL205,L209,Y213 (Figure 23). Taken together with the radioligand displacement
assay, these analyses indicate that mutation of the TM5 GxxxGxxxL motif in TP
allows normal formation of the high affinity receptor-Gq complex at the cell
surface.

Disruption of the TM5 GxxxGxxxL motif modifies TP homodimerization
As outlined in Chapter 1, and in previous reports from the laboratory, the TP
physically associates to form homodimers (70, 122, 123). The molecular
determinants of TP homodimerization have not been defined, nor has the precise
role contribution homodimerization to TP expression and function. However
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Figure 23: Co-immunoprecipitation of Gq with HA-TPWT or HATPL205,L209,Y213. Lysates from HEK 293 cells transfected with empty
pcDNA3 (lane 1), HA-TPWT (lane 2) or HA-TPL205,L209,Y213 (lane 3) were
subjected to immunoprecipitation with anti-HA. In lane 4 lysate is from E
Coli expressing an unrelated HA-tagged control (HA-GST-PI3 kinaseSH2 domain; supplied by the manufacturer). The upper blot was stained
with anti-TP antibody. Molecular species corresponding to
unglycosylated TP and differentially glycosylated TP are indicated. The
lower blot was probed with an anti-Gq antibody. A representative
experiment, which was repeated with similar results, is shown.
Densitometric quantification of Gq relative to HA-TP showed no
difference between TPWT and TPL205,L209,Y213 transfected cells. Data are
representative of n=3.
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across GPCR studies, one or more TMs have been frequently implicated in dimer
formation and function (107, 128, 137). Given the outward facing orientation of
TP-TM5 GxxxGxxxL motif, thus positioned for intermolecular protein interaction,
we examined whether homodimerization was modified in the TP L205, L209, Y213
mutant. BRET studies were performed, using the optimized protocol outlined in
Chapter 2, with TPWT and TPL205, L209, Y213 were fused at their C termini to either
rLUC (energy donor) or YFP (energy acceptor) and energy transfer quantified as
a measure of dimerization. As outlined in Chapter 2 (see Figure 6) in BRET
saturation experiments, the donor-tagged receptor is held steady and the
acceptor-tagged receptor (whose expression is quantified independently as fold
over basal total YFP emission) is gradually increased. A saturable BRET curve
indicates a specific interaction of the two protomers to form a dimer while the
concentration of acceptor at which the BRET signal reaches 50%, the BRET 50,
reflects the affinity of individual promoters for each other (169).
TPL205, L209, Y213 retained the capacity to dimerize, however the BRET50 for TPL205,
L209, Y213

homodimerization was significantly right shifted (BRET 50 = 1.83 ± 0.1,

n=5) compared to the TPWT-TPWT (BRET50 = 1.4 ± 0.08, n=4), indicating reduced
efficiency in formation of the homodimer when the TM5 GxxxGxxxL motif was
disrupted (Figure 24A,B, Figure 25). To confirm impaired homodimerization of
the mutant receptor, BRET was measured in HEK 293 cells expressing a fixed
ratio of rLuc-TPWT + YFP-TPWT (1:7) and competition by unfused TPWT or TPL205,
L209, Y213

examined. As expected, TPWT efficiently competed for the interaction of
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(A)

(B)

rLuc-TPL205,L209,Y213 +
YFP-TPL205,L209,Y213

rLuc-TPWT +
YFP-TPWT

(C)

(D)

rLuc-IP +
YFP- TPL205,L209,Y213

rLuc-IP +
YFP-TPWT

Figure 24: Homo- and hetero- dimerization of TPWT and TPL205,L209,Y213 by BRET. Saturable BRET
was observed for rLuc- (donor, 0.25µg) + YFP- (acceptor, 0.125µg – 0.75µg) fused pairings of (A)
TPWT-TPWT, (B) TPL205,L209,Y213-TPL205,L209,Y213 (C) IPWT - TPWT or (D) IPWT - TPL205,L209,Y213 in transiently
transfected HEK 293 cells. Experiments are representative of n=4-6. Data are milli BRET units plotted
against fold over basal total YFP emission (a measure of YFP-fused acceptor receptor expression).
Individual BRET50 values for are indicated by the dotted gray lines.
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Figure 25: Quantification of homo- and hetero- dimerization of
TPWT and TPL205,L209,Y213 by BRET. BRET50 values were calculated from
4-6 individual BRET saturation experiments (as shown in Figure 24).
Data are mean BRET50 values ± SEM from n=4-6. **p<0.005 relative to
all other data sets.
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rLuc-TPWT and YFP-TPWT reducing the BRET signal in a concentration
dependent manner. TPL51, L54, in which the TP-ICL1 GxxxG motif, G51ARQG55,
was mutated, was as efficient as the TPWT in competition for rLuc-TPWT-YFPTPWT interaction while, in contrast, TPL205, L209, Y213 did not alter the BRET signal
confirming its relative deficiency for dimer formation (Figure 26). Together these
data indicate the importance of TP-TM5 GxxxGxxxL for efficient TP
homodimerization and suggest that normal homodimerization may be critical for
efficient signal transduction.

TM5 GGL domain disruption does not modify TP-IP heterodimerization or
function
The studies thus far indicate that the GxxxGxxxL motif in TM5 of the TP is
important for efficient homodimerization and that its disruption suppresses
receptor signaling. As previously described (Chapter 1, Figure 15A), the TP can
interact with the IP, a Gs-cAMP coupled receptor, to form a heterodimer (121).
When heterodimerized with the IP, the TP’s microdomain localization, signal
transduction and regulation is markedly altered with reduced “normal”
transduction of Gq-inositol phosphate signal in response to TP agonists and a
concomitant switch to signal via the Gs-cAMP pathway in an IP-like manner
(122). This signaling shift likely contributes to the restraint placed on the TP via
the IP and to the increased risk of cardiovascular disease in individuals
heterozygous for signaling deficient IP mutants (125).
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***
NS

Figure 26: Competition of TPL205,L209,Y213, TPL50,L54, and TPWT for
binding with TPWT by BRET. Competition for BRET in rLUC-TPWT +
YFP-TPWT (constant 1:7 ratio) transfected HEK 293 cells by cotransfection with HA-TPWT, HA-TPL205,L209,Y213 or HA- TPL51,L54. Data
are normalized to BRET in rLUC-TPWT + YFP-TPWT transfected cells
without co-transfection of a competing receptor (set to 1) and are
mean ± sem of n=3-4. ***p<0.0001; ns = non significant.
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We next asked whether disruption of the TP TM5 GxxxGxxxL motif modifies
TP-IP heterodimerization and what, if any, functional changes are seen within
the paradigm of TP-IP-Gs signaling in response to TP activation. Interestingly,
and in stark contrast to the homodimer studies, disruption the TM5 GxxxGxxxL
motif did not modify heterodimerization of the TP with the IP – the BRET
saturation curves and BRET50 for TPL205, L209, Y213-IP (1.24 ± 0.06, n=6) was
indistinguishable from the TPWT-IP (BRET50 = 1.26 ± 0.06, n=6) (Figure 24C,D,
Figure 25). Concordantly, U46619-induced cAMP generation, the signature
“switch” in TP signaling from the Gq pathway to the Gs pathways, was not
different between TP-IP and TPL206 L209,Y213-IP in transfected HEK 293 cells or
MEG-01 cells (Figure 27). Thus, while the TM5 GxxxGxxxL motif appeared
critical for efficient TP homodimerization and Gq-signaling, this motif did not
contribute to TP-IP heterodimerization or function. These data support the
concept that distinct molecular interactions drive the physical association of the
TP-TP and TP-IP dimers and their downstream signaling.

A TM GxxxGxxxL motif is found in numerous class A GPCRs
Given that a TM GxxxGxxxL motif was functionally relevant in at least two other
GPCRs, the ß2-adrenoreceptor and the -factor yeast receptor (104, 115), we
searched the SwissProt database (http://prosite.expasy.org/scanprosite/) for
human GxxxGxxxL-containing GPCRs. Sixty-nine receptors were identified of
which, after removal of olfactory (24 hits), taste (2 hits) and orphan (9 hits)
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(A)

(B)

L

Figure 27: Cyclic AMP Signaling through TPWT or TPL205,L209,Y213
heterodimerized with the IP. The TP agonist (U46619) simulated a robust
cAMP response in (A) HEK 293 cells or (B) Meg-01 cells co-transfected with
IP + TPWT (closed circles) or IP + TPL205,L209,Y213 (open circles), compared to
cells transfected with IP alone (open triangles). No difference in cAMP
signaling was observed between IP+TPWT versus IP + TPL205,L209,Y213
transfected cells in either model. Data are % of maximum cAMP response
(in IP + TPWT transfectants) and are mean ± SEM of n=3-4.
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receptors, 22 GPCRs were identified that contain one or more TM GxxxGxxxL
motifs (Table 2). Interestingly, all but one of these 22 was Class A GPCRs
suggesting a particular prevalence of this motif among rhodopsin-like GPCRs.
The significance of this finding for potential novel therapeutic development is
discussed in the following section.

A peptide targeted against a TM GxxxGxxxL motif modifies TP signaling
As previous mentioned, the GxxxGxxxL motif is significant to the function of other
membrane proteins. One set of elegant studies explored targeting this TM motif
in the αIIbβ3 integrin complex using a Computed Helical Anti-Membrane Protein
(CHAMP peptide; Figure 28) intended to mimic the interaction of the individual
integrin protomers. Interestingly, this peptide, termed β-CHAMP by its creators,
modifies integrin function in transfected cells, micelles, and in platelets (128,
142). We obtained a quantity of this CHAMP and examined the impact on TP
signaling. Treatment of HEK 293 cells transiently transfected with TP with 1 mM
CHAMP peptide 30 minutes prior to U46619 stimulation led to a significant
reduction in maximal signaling capacity (11.8 ± 3 % (p<0.001)) compared to
control TP-transfected cells (Figure 29). The small magnitude of the CHAMP
effect likely reflects that this peptide was computationally designed to interact
with a helical domain of the αII integrin, accounting for surrounding amino acids
in the domain, and thus was not optimized to interact with the TP TM5
GxxxGxxxL domain. Despite this caveat, it was possible to pharmacologically
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Table 2: Prevalence of the GxxxGxxxL motif in GPCR transmembrane domains. Prosite
scan of the UniProt/SwissProt protein database (release 2013_01) for the motif G-x(3)-G-x(3)L. Filters were set for species = homo sapiens, description = receptor and size >300 and
<550.

GPCR
family

GxxxGxxxL
Sequence

Residues

TM

5-hydroxytryptamine receptor 1A

A

GIIMGTFIL

348 - 356

6

5-hydroxytryptamine receptor 1E

A

GLILGAFIL

294 - 302

6

5-hydroxytryptamine receptor 5A

A

GILIGVFVL

288 - 296

6

12-(S)-hydroxy-5,8,10,14eicosatetraenoic acid receptor

A

GLECGLGLL

22 - 30

1

1A adrenergic receptor

A

GVILGGLIL

30 - 38

1

GIVVGCFVL

275 - 283

6

1B adrenergic receptor

A

GLVLGAFIL

49 - 57

1

GIVVGMFIL

297 - 305

6

ß1 adrenergic receptor

A

GIIMGVFTL

327 - 335

6

ß2 adrenergic receptor

A

GIIMGTFTL

276 - 284

6

ß3 adrenergic receptor

A

GLIMGTFTL

295 - 303

6

Cannabinoid receptor 2

A

GSLAGADFL

74 - 82

2

Galanin receptor type 2

A

GLIWGLSLL

147 - 155

4

Glucagon receptor

B

GIGWGAPML

269 - 277

4

Muscarinic acetylcholine receptor M1

A

GITTGLLSL

29 - 37

1

Muscarinic acetylcholine receptor M5

A

GIMIGLAWL

148 - 156

4

Neuromedin-U receptor 1

A

GAVWGLAML

183 - 191

4

Neuromedin-U receptor 2

A

GIVWGFSVL

168 - 176

4

Neuropeptide Y receptor type 2

A

GLAWGISAL

170 - 178

4

Opsin-5

A

GFFFGCGSL

113 - 121

3

Oxoeicosanoid receptor 1

A

GLWVGILLL

215 - 223

4

P2Y purinoceptor 4

A

GLLFGVPCL

206 - 214

5

Proteinase-activated receptor 4

A

GHMYGSVLL

158 - 166

3

Thromboxane A2 receptor

A

GLSVGLSFL

205 - 213

5

Receptor
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Figure 28: The β-CHAMP peptide. Sequence of the anti-αIIb CHAMP peptide,
and computational model of anti-αIIb bound to the αIIb TM domain. The model
predicts that anti-αIIb (red stick: backbone, white: space filling) recognizes the
“hot spot” on the αIIb-TM binding surface (light blue) with spatial
complementarity at the helix-crossing site of the peptide and integrin. Adapted
from: Caputo, G. A., R. I. Litvinov, W. Li, J. S. Bennett, W. F. Degrado, and H.
Yin. 2008. Computationally designed peptide inhibitors of protein-protein
interactions in membranes. Biochemistry (Mosc.). 47: 8600–6.
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Figure 29: Inositol Phosphate Signaling through TP in presence of
the β-CHAMP. Maximal inositol phosphate (InosP) generation was
reduced by 11.8 ± 3 % (p<0.001) in TPWT transfected HEK 293 cells
treated with the CHAMP peptide (open circles) compared to untreated
TPWT transfected cells (closed circles) . There was no significant
change in EC50. Data are % of maximum response (in TPWT) and are
mean ± SEM; n=6.
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replicate the signaling deficiency associated with mutation of the TP TM5
GxxxGxxxL, an encouraging result that opens the possibility that a TP TM5
GxxxGxxxL-designed peptide might provide a new approach to antagonize the
TP.

Introduction of a peptide derived from the TP TM1 modifies receptor
signaling
GPCR dimerization studies report the importance of TM1 for receptor
dimerization. For the TP, TM1 was reported as relevant for heterodimerization of
the TP and TPß isoforms (170) although neither homodimer was examined. We
developed an approach to examine how interference with TP TM1 can alter
receptor function. An expression construct was designed to express the first
transmembrane domain of the TP (TM1), comprising residues R23 through T59
and adding necessary elements to provide for constitutive, stable expression
within the cell by virtue of insertion into the pNTAP vector (see Chapter 2,
Constructs, Pages 21-24; Figure 4). HEK 293 cells were transiently transfected
with TPWT either alone or with the TM1 peptide and U46619-induced inositol
phosphate signaling examined. Surprisingly, in preliminary studies, there was a
significant increase in maximal signaling capacity (62.6%, n=2) when TP-TM1
was co-expressed compared to control (Figure 30), with no change in basal
signaling. These early results provide evidence that introduction of a domaintargeted peptide can reduce TP signaling capacity, as with the CHAMP peptide,
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Figure 30: Inositol phosphate signaling through TP in presence of
TM1 peptide. Maximal inositol phosphate (InosP) generation was
increased in TPWT cotransfected with the TP TM1 peptide (open circles)
compared to TPWT (closed circles) in transfected HEK 293 cells.
Preliminary studies (n=2) are shown.
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but also can positively impact signaling, underscoring the complexity of TP
receptor function and the precise functional contribution of distinct receptor
domains. Refined understanding of these processes may lead to development of
targeted peptides or small molecular that modify receptor function in a precise
and highly specific manner to give a desired effect.
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CHAPTER 5: DISCUSSION

A role for homodimerization in TP regulation
Having established that there is no significant change in TP mRNA expression
levels in response to short term receptor activation (Figure 12, Figure 13), we
concluded that increased auto-upregulation of receptor surface expression was
likely under post-translational control. We turned to the possibility of receptor
homodimerization as a means of controlling receptor trafficking and expression.
Reports vary as to the contribution of homodimerization to GPCR function,
however there is substantial evidence that homodimerization is necessary for
normal receptor surface expression (104, 109, 114, 118, 171, 172) and that a
dimeric pair coupled to a single G protein forms the basic signaling unit (100,
108, 173). Dimerization-deficient GPCRs fail to traffic normally to the cell surface,
while ER retained GPCRs can force ER retention of their WT counterparts in a
dominant negative manner (115).
Given the published evidence for a regulatory role of homodimerization, together
with previous work in the lab showing that the TP appears on western blots of
cell lysates at double the expected molecular weight, and that TP and TPß coimmunoprecipitate in transfected cells (122), we directly assessed whether the
TP formed homodimers. There are significant caveats associated with the
analysis of GCPR dimerization in broken cell preparations by
immunoprecipitation and western blotting. For example, the use of detergents to
disrupt cells can cause dimers to dissociate; however, a gentle disruption
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process can allow aggregates to remain giving the appearance of dimeric
species on western blot. A review of the many and varied methods used to detect
receptor dimerization included such as western blotting, co-immunoprecipitation,
cross-linking, FRET (a close relative of BRET but using a fluorescent donor
instead of rLuc), yeast two-hybrid analysis, functional complementation, and
crystallography (164). This comprehensive review also discussed the dangers of
using highly disruptive methods of analysis, and those that did not employ the
use of whole, live cells, and noted substantial caveats and limitations associated
with many of the methods listed above.
We chose, therefore, to establish a method to examine TP dimerization in living
cells by bioluminescence resonance energy transfer (BRET), a minimally
invasive method that would generate minimal false positives and negatives
derived from artifact. As outlined in Chapter 2 (Figure 8, Figure 10, Figure 11),
we rigorously assessed the standard BRET assay for issues of signal stability
and quantitative accuracy, ultimately developing a tightly controlled, sensitive
BRET experimental platform to assess receptor dimerization in living cells. In
advancing the BRET assay we determined that substrate stability, both in
solution before addition to the cells and during the lag time while reading an
entire 96 well plate, is a critical parameter that should be carefully assessed and
controlled. In our hands, resting the substrate for 20 minutes and applying fresh
substrate to a small number of wells immediately before collecting light emission
markedly improved the internal consistency of the assay and reduced noise
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sufficiently to allow precise analysis of dimer formation that may have been lost
in the previous iteration of the BRET assay. While this approach still relies on
transfection of receptors (fused to a donor or acceptor moiety) in standard cell
lines, continuing improvement in antibodies to native receptors and development
of labeled ligands is opening avenues to similarly precise assessment of native
dimers.
Establishing that BRET occurs in donor/acceptor co-transfected cells is in itself
insufficient evidence that physiologically relevant dimers are likely to form. BRET
can occur non-specifically when donor and acceptor are co-expressed (so-called
bystander BRET), or at such disproportionate levels of one promoter to the other
that the physiological interaction is questionable.
Construction of a BRET saturation curve establishes specificity (saturation) and
affinity (the BRET50). In our work, BRET studies confirmed the formation of
specific and saturable interaction of TP with itself (Figure 14) with a high affinity
indicating that the dimer may from in a physiological setting. It is worth noting that
although we refer to this interaction as homodimerization, the BRET assay we
used does not distinguish between dimers and high order oligomers and it
remains an open question whether the number of receptors that associate is two
or more and what relevance this may have for receptor regulation and function.
We reasoned that, if homodimerization contributed to auto-upregulation of the TP
in response to agonist activation, then dimerization would be modified
(presumably increased) by agonist. However, analysis of agonist effects on TP
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homodimerization may have been confounded by a limitation of the BRET assay.
To propagate signal, agonist binding relies upon changes in receptor
conformation and such changes can shift the orientation of the donor and
acceptor molecules within the dimer. Thus, a change in distance or orientation of
the donor and acceptor can change the nature and magnitude of the resonance
energy transfer reaction, confounding the output of the assay in an unpredictable
manner. Indeed, although we did not observe changes in TP BRET in response
to agonist treatment, significant changes were evident upon addition of
antagonist treatment (Figure 17), suggesting that this BRET assay is not a
reliable method to define agonist-dependent changes in dimerization. Being that
homodimerization is linked to successful signaling, and that signaling is
necessary for the auto-upregulation to occur, any successful assay would have
to account for this tight intertwining of processes as well. Additionally, the
increasing power of molecular modeling could be employed to gain some
understanding of the ways in which ligand binding can alter the conformation of a
target receptor, as has already been shown for the β(1)- and β(2)-adrenergic
receptors (174). This, combined with knowledge of dimerization interfaces
determined using molecular methods such as those we employed, could shed
light on how ligand binding might influence receptor dimerization.
Thus, while it remains possible that TP homodimerization contributes to its
auto-upregulation in response to agonist, this has not yet been experimentally
determined. Such a study could be carried out through the use of different
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mutants of the TP in future studies, including those that are retained in the ER,
which might serve as a dominant negative to anchor a wild-type TP, reducing
surface expression. However, the confounding effects of disrupted dimerization
on agonist-dependent signaling raise substantial challenges for understanding
how dimerization impacts ligand-dependent events downstream of the primary
signal. Alternative approaches include the use of donor- or acceptor- labeled
ligands or antibodies to the native receptors in which energy transfer might not
be impacted by conformational changes in either or both receptors

Heterodimeric partners of the TP and modification of signal transduction
Co-immunoprecipitation of TP with the IP was reported previously in the lab
(123). We also sought to examine, therefore, by BRET, the relative propensity of
the TP to heterodimerize with the IP, as well as other prostanoid receptors, a
significant strength of the BRET assay compared to co-immunoprecipitation. We
found that TP forms high affinity heterodimers with the IP (Figure 15), a
receptor that is distinct in its sequence (33.6% amino acid homology, FASTA
alignment), membrane microdomain localization, regulation and effector signaling
(94, 121–123). This highly suggestive evidence for TP-IP heterodimerization
complements our previous observation that TP agonists evoke a PGI 2-IP like
signal, cAMP generation, through the TP-IP heterodimer (Figure 27), coincident
with suppressed canonical TP-inositol phosphate generation (5, 123). In addition,
we also observed TP dimerization with the PGD2 receptor, the DP1, although the
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lower affinity for TP-DP1 interaction suggests that this heterodimeric species may
form less readily that the TP-IP, given proper physiological conditions (Figure
15). However, it remains possible that TP-DP1 heterodimerization may form
more readily in specific contexts including the relative expression levels of the
different receptors (e.g. if IP is lower that DP1 or absent) or ligand activation of
one of the receptors modifies heterodimerization processes (e.g. if DP1
activation increased its affinity for the TP). Such intricacies of the relative
formation of TP containing heterodimers require further in-depth analyses and
approaches other than BRET.
Our studies of TP-IP heterodimer signaling, which occurs in transfected and
native cells (94, 121, 123), touch upon interesting concepts regarding
asymmetrical signaling in dimeric pairs. With receptors like the dopamine D2
receptor (108), GABAB receptor (175), and the metabotropic glutamate receptor
(176), whose basic signaling unit consists of a pair of GPCRs coupled to one G
protein, signaling can occur asymmetrically through binding of ligand to the first
protomer and subsequent activation of the G protein by the second protomer.
This signaling modality would explain the how the TP-IP heterodimer can bind TP
agonists (presumably at the TP binding site) while eliciting a G s-mediated
signaling response through asymmetric activation of the IP. While our work with
the GxxxGxxL TP mutant supports the paradigm of asymmetric TP-IP signaling
(see below), whether the TP homodimer signals asymmetrically remains to be
experimentally determined.
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Exploration of the role of the GxxxGxxxL motif in TP dimerization and
function
Protein-protein interactions are ubiquitous to biological processes and are vital
for signaling complex assembly. Compared to cytosolic protein regions, relatively
little is known about the interaction of membrane embedded proteins within lipid
bilayers, although there is substantial and increasing interest in therapeutic
targeting of TM interactions (138). GPCRs are characterized by their 7
transmembrane spanning helical regions, which are capable of intramolecular
interactions that define tertiary and quaternary receptor structure and function
(177, 178). The GxxxG interaction motif, first described in homodimerization of
the single TM sialglycoprotein glycophorin A (GpA), has been identified as a high
frequency TM motif across diverse protein families (135, 179). In GpA, as in
other transmembrane proteins, residues that neighbor the GxxxG domain appear
critical and are thought to provide a three-dimensional structure within the TM
helix creating the protein-protein interface. In one particular subclass, termed
“glycine zippers”, a small residue (glycine, alanine or serine) is located 3
positions before or after the GxxxG motif (136). More generally, large residues
(isoleucine, valine or leucine) are commonly found within 1 or 2 positions of the
GxxxG pair (135), forming a groove (the glycines) and ridges (the large residues)
arrangement. In the case of the TP TM5 GxxxGxxxL motif, we determined a
similar arrangement with a groove created by S201G205G209 and a ridge created
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leucines 203, 206, 210 and 213 (see Figure 31). The positioning of Leu213 three
residues after the GxxxG pair serves to align the GGL triplet along the same helix face (see Figure 3) and was observed in multiple other Class A human
GPCRs (Table 2), as well as  integrins (142).
To define its contribution to TP function, we mutated the small-small-big
arrangement of G205xxxG209xxxL213 motif to L205xxxL209xxxY213 , similar to other
studies of this specific motif (115, 139, 141, 142), an approach designed to
disrupt the grove and ridge alignment along the outer-side of TM5 (see Figure 3,
Figure 31). As outlined in Chapter 4, signaling of the TPL205,L209,Y213 via the Gqinositol phosphate cascade was markedly reduced in both transfected HEK 293
cells and Meg-01 platelet-like cells. Given the role of GxxxG motifs in helical
packing (135), we considered that this loss of function might be due to improper
processing of the correctly folded receptor at the cell surface. However,
comparable cell surface expression of the wild type and TM5 GxxxGxxxL mutant
receptor was evident by flow cytometry in both in vitro models (Figure 20) and no
alteration in processing of the fully glycosylated receptor was evident by
fluorescence microscopy (Figure 19) or immunoblotting (Figure 23). Further,
displacement analysis using a range of TP ligands revealed no difference in the
ligand binding properties of TPL205,L209,213 compared TPWT and both the mutant
and WT receptor displayed high agonist affinity (Figure 21), consistent with
normal G protein association and the comparable levels of Gq that accompanied
the wild type or mutant receptor in co-immunoprecipitation experiments
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Leu203

Ser201
Gly205
Gly209

Leu210

Leu213

Leu214

Figure 31: Modeling of the “groove and ridge” structure of
the GxxxGxxxL motif. Modeling of the TPα TM5 highlighting
the leucines that neighbor G205 and G209 and L213. By analogy
with glycophorin A, the small residues, S201, G205 and G209,
align to create a groove (green), while the large residues L203,
L206, L210 and L213 form an adjacent ridge (yellow). (Credit:
Scott Gleim/Hwa Lab, Yale University School of Medicine)
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(Figure 23). Together these analyses clearly indicate no major role for the TM5
GxxxGxxL motif in processing of the TP to form a high affinity receptor-Gq
complex at the cell surface.
Homodimerization of GPCRs appears universal across the superfamily (102,
119, 165). Given the established contribution of GxxxG motifs to helix-helix
interactions, the extensive evidence that TMs are critical for GPCR
homodimerization and the outward facing orientation of the G205xxxG209xxxL213
triplet in TP TM5 we considered whether this motif contributes to TP
homodimer formation. We found that while saturable BRET was achieved, the
BRET50 for TPL205,L209,Y213 homodimerization was significantly right-shifted
compared to TPWT (Figure 24,Figure 25). Thus, while TPL205L209Y213 protomers
can dimerize, they do so with a reduced affinity. Importantly, we confirmed
independently that TPL205,L209,Y213 was unable to compete for TPWT-TPWT
interaction, confirming the mutant’s dimerization deficiency (Figure 26). Thus,
similar to the ß2-AR (115, 130) and yeast -factor (104, 180) receptors, a TM
motif GxxxGxxxL is necessary for normal efficient TP homodimerization.
In the case of ß2 adrenergic receptor, disruption of the TM6 GxxxGxxxL motif
right shifted the BRET50 for homodimerization coincident with reduced cell
surface receptor expression (115). Our data showing normal processing (Figure
19), cell surface expression (Figure 20) and G protein association of
TPL205,L209,Y213 (Figure 23) despite impaired dimerization suggests that for the
TP the two processes, homodimerization and cell surface expression, are
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independent. Alternatively, it may be that the level of TPL205,L209,Y213
homodimerizes sufficiently to traffic to the cell surface but that the reduced
protomer affinity significantly modifies the efficiency with which signal is
transduced. Our data does not reveal how activation of Gq via TPL205L209Y213 is
reduced but one possibility is the formation of a suboptimal conformation of the
TPL205L209Y213 homodimer, impacting the receptor dimer’s ability to undergo the
necessary conformational shift to fully activate Gq.
Having determined that the G205xxxG209xxxL213 motif does in fact play a
significant role in TP homodimer formation and function, we also were interested
in evaluating the effects of mutation of this motif on the TP/IP heterodimer.
Interestingly, mutation of the G205xxxG209xxxL213 motif did not impact either
heterodimerization with the IP, or TP agonist-induced cAMP generation through
the heterodimer. BRET assays showed no significant change in BRET 50 for the
TP-IP heterodimer upon substitution of TPL205,L209,213 for TPWT, and the mutant
TPα allowed for activation along the TPα-IP-Gs pathway in response to TP
agaonist with no changes in maximal signaling or EC50. Thus, it appears that the
TP TM5 GxxxGxxxL motif contributes selectively to homodimerization and that
distinct receptor regions direct formation of the TP-IP heterodimer. Further, the
normal TP-agonist-cAMP signal propagated by the TPL205,L209,213-IP heterodimer
supports the concept of asymmetric signaling (see below).

Promise of the GGL as a target for future therapeutics
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It has been over a decade since the GPCR dimerization was first reported (181–
183). Since that time, much has been learned about the molecular mechanisms
of GPCR dimerization and the biological relevance for receptor function. The
most well established model of GPCR dimerization holds that two receptors
couple to one G protein (108, 173). In heterodimers, one promoter typically
dominates the downstream signal transduced, and hence the biological outcome
(108). For example, in heterodimers of the B2 receptor for the vasorelaxant
bradykinin and the AT1 receptor for the vasoconstrictor angiotensin II, the latter
dominates leading to enhanced AT1-Gq signaling and vasoconstriction (105,
165). It remains unclear whether ligation of one or both protomers is optimal and
to what extent G protein activation is symmetrical (the agonist activates the
protomer that is directly associated with the G protein) or asymmetrical (the
agonist indirectly activates the G protein through the non-G protein associated
protomer) (103, 173). In the case of the serotonin type 4 receptor homodimer,
evidence supports asymmetrical G protein activation through one ligand binding
to its protomer but activating signaling via the companion protomer (173). For the
TP-IP, we established that the IP dominates the heterodimer’s signaling through
the Gs-cAMP cascade but that agonists for either protomer could activate the
complex (123). Our observations that the TM5 GxxxGxxxL mutant did not
support normal Gq-inositol phosphate signaling in the homodimer but was fully
capable of propagating a normal cAMP response to TP agonist in the IPTP
heterodimer, provides further support for the 2-receptors-1-G-protein model and
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for asymmetrical G protein activation through one protomer in a dimeric complex
(in this case agonism of the TP led to activation of the IP-associated Gs in the
TP-IP heterodimer).
We reported that the shift in TP function to Gs signaling when dimerized with the
IP likely contributes to the restraint placed by the PGI2-IP system and the TXA2TP system in vivo (102, 115, 124). It is, therefore, very promising to uncover a
molecular region the selectively reduces TP homodimer function without altering
activation and signaling of TP-IP heterodimer. Efforts to antagonize the TP have
proved clinically disappointing (12, 147), perhaps because TP antagonists block
activation of the TP in both its TP-TP homodimeric (Gq-coupled) and TP-IP
heterodimeric (Gs-coupled) complexes (102). Our work opens novel avenues to
biased interference with the TP-TP homodimer while sparing the function of the
TP-IP heterodimer and its beneficial cardiovascular biological effects. Arguably,
such an approach should be superior to inhibitors of thromboxane synthase, and
even selective inhibition of platelet COX-1 with low dose aspirin, because the
endogenous ligand acting at the TP-IP heterodimer would be spared.
Recently, computationally designed peptides directed at the GxxxGxxxL motif
that mediates interaction of the αIIbβ3 integrins were reported to modify integrin
function in platelets (128, 142). We propose that such a peptide targeted at TP
TM5 GxxxGxxxL domain may provide a novel approach to biased TP
antagonism. Conceivably, such selective targeting of the TP homodimer would
allow us to modify signaling in cell types with high TP-TP expression, such as
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platelets, while largely preserving the function of cells that have a higher TP-IP
dimer population, such as macrophages (125).
It is also worth considering the promise of the GxxxGxxxL domain in light of our
examination of the motif’s presence in other GPCRs (Table 2). In our analysis of
114 GPRCs, a TM GxxxGxxxL motif was identified in 22 receptors including the
TP. The conservation of this sequence within the transmembrane domains of
other receptors underscores its likely importance as a specialized interaction
motif, as does the lack of incidence of SNPs appearing within this motif in the TP,
in contrast to the large number of coding SNPs reported elsewhere in the
receptor (184). This motif may play a similar role in dimerization of other proteinprotein interaction for the 21 other receptors identified, a topic for future studies.
It may be that this motif provides a “druggable” target for the development of a
new class of precisely tailored therapeutics for specific receptor dimers. The
prevalence of the motif suggests that it is common enough to be worth pursuing,
while uncommon enough to limit off-target effects with rationale design of the
targeted peptide or molecule. Indeed, exciting advances in computational design
of peptides to precisely target the TM domains (128) open the possibility of
design novel reagents that can selectively target the TP TM5 GxxxGxxxL
domain, and by extension other TM domains in GPCRs of interest, while
minimizing the effects of such interference in nearby receptors that also contain
the functional domain. Such precise tools may allow assessment of native GPCR
dimers in relevant normal cells, without the need for addition of an energy donor
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or acceptor moiety and expression in a non-native cell line, and in animal models
of normal and disease receptor function. Perhaps more importantly, precise
targeting of a specific receptor domain, modifying one signaling arm, may allow
development of a novel class of therapeutics designed to bias receptor function
toward a desired beneficial outcome.
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